documents incorporated reference specified portions registrants proxy statement filed commission pursuant regulation connection registrants annual meeting stockholders held may incorporated reference part iii report based closing price per share june excludes shares registrants common stock held executive officers directors stockholders whose ownership exceeds registrants common stock outstanding june exclusion shares construed indicate person possesses power direct indirect direct cause direction management policies registrant person controlled common control registranttable contents gilead sciences inc annual report table contents part item business item risk factors item b unresolved staff comments item properties item legal proceedings item submission matters vote security holders part ii item market registrants common equity related stockholder matters issuer purchases equity securities item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures item b information part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accountant fees services part iv item exhibits financial statement schedules signatures rights various trademarks copyrights trade names used business including following gilead sciences hepsera viread vistide ambisome emtriva truvada atripla registered trademark belonging bristolmyers squibb gilead sciences llc macugen registered trademark belonging osi pharmaceuticals inc sustiva registered trademark bristolmyers squibb company tamiflu registered trademark belonging f hoffmannla roche ltd flolan registered trademark glaxosmithkline inc report also includes trademarks service marks trade names companiestable contents annual report including section entitled managements discussion analysis financial condition results operations contains forward looking statements regarding future events future results subject safe harbors created securities act amended securities act securities exchange act amended exchange act words expect anticipate target goal project intend plan believe seek estimate continue may could might variations words similar expressions intended identify forwardlooking statements addition statements refer projections future financial performance anticipated growth trends businesses characterizations future events circumstances forwardlooking statements based forward looking statements current expectations future events statements guarantees future performance involve risks uncertainties assumptions difficult predict actual results may differ materially suggested forward looking statements various reasons including identified risk factors beginning given risks uncertainties cautioned place undue reliance forward looking statements forward looking statements included report made date hereof except required federal securities laws rules regulations us securities exchange commission sec undertake specifically decline obligation update statements publicly announce results revisions forward looking statements distribution report whether result new information future events changes assumptions otherwise part item business overview gilead sciences inc gilead incorporated delaware june biopharmaceutical company discovers develops commercializes innovative therapeutics areas unmet medical need mission advance care patients suffering lifethreatening diseases worldwide headquartered foster city california operations north america europe australia date focused efforts bringing market novel therapeutics treatment lifethreatening infectious diseases expanded research development commercial focus include respiratory cardiopulmonary disease acquisitions two companies continue seek add existing portfolio products internal discovery clinical development programs active product acquisition inlicensing strategy acquired following two companies respiratory cardiopulmonary disease areas august acquired corus pharma inc corus company engaged drug discovery related respiratory infectious diseases coruss lead product candidate aztreonam lysine inhalation inhaled antibiotic activity gramnegative bacteria including pseudomonas aeruginosa cause lung infections patients cystic fibrosis cf completed enrollment second phase study january expect data study midyear pending positive outcome second phase study anticipate file new drug application nda us food drug administration fda regulatory approval aztreonam lysine treatment cf united states second half addition aztreonam lysine exploring inhaled compounds treatment respiratory infections november acquired myogen inc myogen company engaged primarily drug discovery related cardiopulmonary disease cardiovascular disorders myogens lead product candidate ambrisentan endothelin receptor antagonist potential treatment pulmonary arterial hypertension pah december filed nda treatment pah ambrisentan table contents fda february fda granted us priority review status nda marketing approval ambrisentan established target review date june ambrisentan granted orphan drug status potential treatment pah united states european union exclusive rights ambrisentan united states glaxosmithkline inc gsk holds exclusive rights ambrisentan territories outside united states products truvada tenofovir disoproxil fumarate emtricitabine oral formulation dosed day part combination therapy treat human immunodeficiency virus hiv infection adults fixeddose combination antihiv medications viread tenofovir disoproxil fumarate emtriva emtricitabine promote truvada united states us commercial team sell united states exclusively wholesale channel promote sell truvada european union commercial team distributors australia new zealand commercial team certain latin american countries distributors promote sell truvada japan corporate partner japan tobacco inc japan tobacco addition truvada made available us noprofit prices certain developing world countries included gilead access program exclusive worldwide license patent rights related technology viread emtriva components truvada institute organic chemistry biochemistry part academy sciences czech republic rega stichting vzw together iocbrega emory university emory respectively viread oral formulation nucleotide analogue reverse transcriptase inhibitor dosed day part combination therapy treat hiv infection adults promote viread united states us commercial team sell united states exclusively wholesale channel promote sell viread european union commercial team distributors australia new zealand commercial team certain latin american countries distributors promote sell viread japan corporate partner japan tobacco addition viread made available us noprofit prices certain developing world countries included gilead access program exclusive worldwide license patent rights related technology viread iocbrega atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg oral formulation dosed day treatment hiv infection adults atripla first oncedaily single tablet regimen hiv intended standalone therapy combination antiretrovirals fixeddose combination antihiv medications viread emtriva bristol myerssquibb companys sustiva efavirenz atripla approved commercial sale united states promote atripla joint venture partner bristol myerssquibb company bms united states companys us commercial teams sell joint venture bms bristol myers squibb gilead sciences llc united states exclusively wholesale channel exclusive worldwide license patent rights related technology viread emtriva components atripla iocbrega emory respectively sustiva component atripla licensed joint venture bms filed marketing approval atripla european union bms merck co inc merck october threeway joint venture established three companies emtriva oral formulation nucleoside analogue reverse transcriptase inhibitor dosed day part combination therapy treat hiv infection adults united states europe emtriva also approved part combination therapy treat hiv infection children promote emtriva united states us commercial team sell united states exclusively wholesale channel promote sell emtriva european union commercial team distributors australia new zealand commercial team certain latin american countries distributors promote sell emtriva table contents japan corporate partner japan tobacco exclusive worldwide license patent rights related technology emtriva emory hepsera adefovir dipivoxil oral formulation nucleotide analogue hepatitis b virus hbv dna polymerase inhibitor dosed day treat chronic hepatitis b hepsera approved sale united states treatment chronic hepatitis b adults evidence active viral replication either evidence persistent elevations serum aminotransferases alt ast histologically active liver disease us commercial team promotes hepsera united states sell united states exclusively wholesale channel promote sell hepsera european union commercial team distributors australia new zealand commercial team licensed rights commercialize hepsera solely treatment hepatitis b asia latin america certain territories gsk began selling hepsera japan republic korea taiwan china subject obligation pay us royalties net sales gsk generates hespera exclusive worldwide license patent rights related technology hepsera iocbrega ambisome amphotericin b liposome injection proprietary liposomal formulation amphotericin b antifungal agent treat serious invasive fungal infections caused various fungal species corporate partner astellas pharma inc astellas promotes sells ambisome united states canada promote sell ambisome europe australia new zealand international commercial team also use various distributors promote sell ambisome latin america south america asia japan dainippon sumitomo pharma co ltd handles promotion distribution india mediterranean middle east vistide cidofovir injection antiviral medication treatment cytomegalovirus retinitis patients acquired immunodeficiency syndrome aids vistide approved sale united states promote vistide united states us commercial team sell united states exclusively wholesale channel countries outside united states vistide sold pfizer inc pfizer subject obligation pay us royalties net sales pfizer generates vistide flolan epoprostenol sodium injected medication longterm intravenous treatment primary pulmonary hypertension pulmonary hypertension associated scleroderma spectrum disease new york heart association class iii class iv patients respond adequately conventional therapy march myogen acquired us november entered license agreement distribution supply agreement gsk exclusive rights market promote distribute flolan sterile diluent flolan united states april following table lists aggregate product sales major products thousands total total total product product product sales sales sales hiv products truvada viread atripla emtriva total hiv product sales hepsera ambisome total product sales table contents see item note consolidated financial statements pages included annual report product sales geographic area royalties products tamiflu oseltamivir phosphate oral antiviral available capsule form treatment prevention influenza b tamiflu class prescription drugs called neuraminidase inhibitors tamiflu approved treatment influenza children adults countries including united states japan european union approved prevention influenza children adults united states japan european union developed tamiflu f hoffmannla roche ltd together hoffmannla roche inc roche roche exclusive right manufacture third parties sell tamiflu worldwide subject obligation pay us royalties based percentage net sales roche generates tamiflu worldwide macugen pegaptanib sodium injection intravitreal injection antiangiogenic oligonucleotide treatment neovascular agerelated macular degeneration macugen approved fda united states december sales commenced january february product received marketing approval sale european union macugen developed osi pharmaceuticals inc osi using technology licensed us promoted united states osi pfizer osi holds exclusive rights manufacture sell macugen worldwide subject osis obligation pay us royalties based percentage net sales osi generates macugen worldwide daunoxome liposomal daunorubicin injection liposomal formulation anticancer agent daunorubicin approved sale united states europe certain countries treatment aidsrelated kaposis sarcoma march exclusively licensed worldwide rights sell daunoxome diatos sa diatos terms license agreement diatos obligated pay us royalties based percentage net sales diatos generates daunoxome commercialization distribution us international commercial sales operations marketing subsidiaries australia austria belgium canada france germany greece ireland italy netherlands new zealand portugal spain switzerland turkey united kingdom united states commercial teams promote truvada viread emtriva hepsera direct field contact physicians hospitals clinics healthcare providers involved treatment patients hiv truvada viread emtriva chronic hepatitis b hepsera sell truvada viread emtriva hepsera united states exclusively wholesale channel corporate partner astellas promotes sells ambisome us united states sell truvada viread emtriva hepsera ambisome european union commercial team distributors australia new zealand commercial team promote atripla united states joint venture partner bms respective commercial teams using direct field contact physicians hospitals clinics healthcare providers involved treatment patients hiv promote vistide united states us commercial team sell united states exclusively wholesale channel us commercial team promotes distributes flolan sterile diluent flolan united states promote sell distribute products countries outside united states european union including countries asia latin america middle east africa certain territories enter table contents agreements thirdparty distributors granting exclusive right sell products particular territory specified period time agreements provide collaborative efforts distributor us obtaining regulatory approval product specified territory agreements generally grant distributor right market product territory march initiated evaluation european distribution framework outside existing european subsidiaries result initiated contact certain european distributors intent ultimately terminate distribution agreements product sales three large wholesalers accounting total revenues years ended december combined basis wholesalers accounted approximately product sales united states following table summarizes percent total revenues attributed sales three wholesalers year ended december cardinal health inc mckesson corp amerisourcebergen corp competition products development programs target number areas including viral fungal respiratory cardiopulmonary diseases many commercially available products treatment diseases large number companies institutions spending considerable amounts money resources develop additional products treat diseases products compete available products based primarily efficacy safety tolerability acceptance doctors ease patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing hiv products hiv landscape becoming competitive complex treatment trends continue evolve growing number antihiv drugs currently sold advanced stages clinical development approximately branded drugs available united states hiv products primarily compete fixeddose combination products nucleotidenucleoside reverse transcriptase inhibitors nrti class including combivir lamivudine zidovudine epzicom abacavir lamivudine trizivir abacavirlamivudinezidovudine sold gsk companies hiv products competing nrti class include bms roche although hiv products also compete broadly hiv products boehringer ingelheim gmbh merck abbott laboratories inc tibotec therapeutics division ortho biotech products lp table contents bmss videx ec didanosine ddi became first generic hiv product united states gsks retrovir zidovudine also faces generic competition united states result launch generic zidovudine date little impact generic didanosine generic zidovudine price hiv products however price decreases hiv products may result longer term ambisome ambisome faces strong competition several current expected competitors competition current expected competitors may erode revenues receive sales ambisome ambisome primarily competes vfend voriconazole developed pfizer caspofungin product developed merck marketed cancidas united states caspofungin elsewhere ambisome also competes lipidbased amphotericin b products including abelcet amphotericin b lipid complex injection sold enzon pharmaceuticals inc united states canada japan zeneus pharma ltd europe amphotec amphotericin b cholesteryl sulfate complex injection sold three rivers pharmaceuticals llc worldwide anfogen amphotericin b liposomal sold genpharma sa argentina bms numerous generic manufacturers sell conventional amphotericin b also competes ambisome aware reports least three lipid formulations claim similarity ambisome becoming available outside united states including anticipated entry one formulation greece addition amphiprol amphotericin b made proel pharmaceuticals approved yet commercially available greece formulations may reduce market demand ambisome furthermore manufacture lipid formulations amphotericin b complex formulations found unsafe sales ambisome may negatively impacted association hepsera hepsera faces significant competition existing expected therapies treating patients infected hbv hepsera competes primarily antiviral products baraclude entecavir oral nucleoside analogue developed bms launched united states tyzeka telbivudine oral nucleoside analogue developed novartis pharmaceuticals corporation novartis idenix pharmaceuticals limited idenix launched united states october epivirhbvzeffix lamivudine developed gsk collaboration shire pharmaceuticals group plc sold major countries throughout north south america europe asia hepsera may also face competition clinicalstage candidates including pradefovir mesylate oral antiviral compound developed valeant pharmaceuticals international currently phase clinical trials hepsera also competes established immunomodulatory therapies including introna interferon alfab sold schering plough corporation major countries throughout north south america europe asia pegasys pegylated interferon alfaa injectable drug similar introna sold roche treatment hbv vistide vistide competes number drugs also treat cytomegalovirus retinitis including cytovene iv cytovene ganciclovir sold intravenous oral formulations roche ocular implant bausch lomb incorporated valcyte valganciclovir also marketed roche foscavir foscarnet intravenous drug sold astrazeneca plc vitravene fomivirsen drug injected directly eye sold cibavision tamiflu tamiflu competes relenza zanamivir antiinfluenza drug sold gsk relenza neuraminidase inhibitor delivered orallyinhaled dry powder generic competitors include amantadine rimantadine oral tablets inhibit replication influenza virus biocryst pharmaceuticals inc developing injectable formulations peramivir influenza neuraminidase inhibitor treatment influenza currently phase clinical trials macugen macugen competes primarily visudyne verteporfin injection sold novartis used connection photodynamic therapy lucentis ranibizumab sold genentech inc table contents flolan flolan competes primarily remodulin treprostinil form prostacyclin administered via continuous subcutaneous infusion continuous intravenous infusion sold united therapeutics corporation united states flolan also competes ventavis iloprost inhaled form prostacyclin sold affiliates actelion ltd united states addition one generic pharmaceutical companies may launch attempt launch generic version flolan united states thereafter number companies pursuing development technologies competitive research programs competing companies include specialized pharmaceutical firms large pharmaceutical companies acting either independently together biopharmaceutical companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs anticipate face increased competition future competitors introduce new products market new technologies become available determine existing products new products competitors develop effective effectively marketed sold develop competitive products could render technology products obsolete noncompetitive recover investments resources used develop products collaborative relationships part business strategy establish collaborations companies universities medical research institutions assist clinical development andor commercialization certain products product candidates provide support research programs also evaluate opportunities acquiring products rights products technologies complementary business companies universities medical research institutions information regarding relationships including financial accounting impact business found item note consolidated financial statements pages included annual report commercial collaborations following list representative commercial collaborations year commercial collaboration partner program area signing emory emtricitabine bristol myerssquibb atripla japan tobacco viread truvada emtriva gsk hepsera flolan osi liposome products macugen pfizer macugen vistide sumitomo ambisome roche tamiflu md anderson cancer center hepsera iocbrega atripla viread truvada hepsera vistide astellas ambisome ulehi selex emory university emory april triangle pharmaceuticals inc triangle acquired us january obtained exclusive worldwide license emorys rights purified forms emtricitabine use hiv hbv indications prior july paid royalties emory respect worldwide net sales product containing emtricitabine july royalty pharma purchased respectively royalty interest owned emory exchange elimination emtricitabine royalties payable emory since july paid table contents royalties respect worldwide net sales products containing emtricitabine directly royalty pharma rate proportional share purchase price also july made payment emory connection amendment restatement existing license agreement emory pertained obligation develop emtricitabine hepatitis b indication bristolmyers squibb company bms december entered collaboration bms develop commercialize single tablet regimen truvada bmss sustiva united states combination approved use united states july sold name atripla bms structured collaboration joint venture forming limited liability company called bristolmyers squibb gilead sciences llc terms collaboration bms granted royaltyfree sublicenses joint venture use respective companyowned technologies return granted license joint venture use intellectual property results collaboration economic interests joint venture held us bms based fraction estimated net selling price atripla attributable truvada sustiva respectively adjusted annual basis since net selling price truvada may change time relative net selling price sustiva bmss respective economic interests joint venture may vary annually bms share marketing sales efforts parties providing equivalent sales force efforts minimum number years daily operations joint venture governed four primary joint committees responsible accounting financial reporting product distribution joint venture september bms amended joint ventures collaboration agreement allow joint venture sell atripla canada japan tobacco inc japan tobacco july entered licensing agreement japan tobacco japan tobacco would commercialize hiv product portfolio specifically viread truvada emtriva japan terms agreement received upfront license fee received additional cash payments upon achievement certain milestones japan tobacco also required pay us royalty net sales products japan march viread approved sale japan march emtriva truvada approved sale japan glaxosmithkline inc gsk march myogen acquired us november entered license distribution supply agreement gsk exclusive rights market promote distribute flolan sterile diluent flolan united states april gsk assigned us rights responsibilities respect flolan certain agreements specialty pharmacy distributors extent gross sales flolan united states exceed certain predefined targets supply price paid us gsk flolan decrease sliding scale myogen commenced distribution activities flolan united states distribution supply agreement april april entered licensing agreement gsk providing gsk right commercialize hepsera solely treatment chronic hepatitis b asia latin america certain territories significant include china japan republic korea taiwan agreement retained rights hepsera united states canada europe australia new zealand turkey received upfront license fee milestone payments payable licensing agreement gsk full responsibility development commercialization hepsera treatment hepatitis b territories addition gsk required pay us royalties net product sales hepsera gsks hepatitis product epivirhbvzeffix gsk territories hepsera launched japan republic korea taiwan china osi pharmaceuticals inc osi december completed sale oncology assets osi terms agreement entitled additional payments osi either cash combination cash osi stock osi reaches certain development milestones nx advanced oncology product candidates sold osi table contents related manufacturing agreement produce nx gs l two liposomal drug candidates included sale march entered agreement osi successor eyetech pharmaceuticals inc relating macugen terms agreement osi worldwide rights therapeutic uses macugen responsible research development costs entitled receive payments osi osi reaches certain milestones well royalties worldwide net sales macugen december entered agreement osi fill finish macugen osi initial term ending january pfizer inc pfizer december osi granted pfizer sublicense relating macugen connection sublicense entered license pfizer terms contained agreement osi macugen approved fda united states december sales commenced january february product received marketing approval sale european union august entered agreement pfizer successor pharmacia corporation relating vistide agreement pfizer exclusive right market sell vistide countries outside united states subject payment us percentage net product sales agreement required sell pfizer bulk cidofovir maintain vistide patents connection agreement received upfront license fee cash payment upon obtaining marketing approval europe well certain royalties net sales vistide dainippon sumitomo pharma co ltd sumitomo september entered agreement sumitomo pursuant sumitomo agreed develop market ambisome japan terms agreement received upfront license fee addition entitled receive additional payments certain clinical commercial milestones met well receive royalties ambisome sales japan f hoffmannla roche ltd together hoffmannla roche inc roche september entered development license agreement roche develop commercialize therapies treat prevent viral influenza tamiflu antiviral oral formulation treatment prevention influenza codeveloped us roche original agreement roche exclusive right manufacture sell tamiflu worldwide subject obligation pay us percentage net sales roche generated tamiflu sales november entered first amendment supplement original agreement roche amendment eliminated cost goods adjustments royalty calculation retroactive calendar year future calculations amendment also provided formation joint manufacturing committee review roches existing manufacturing capacity tamiflu global plans manufacturing tamiflu us commercial committee evaluate commercial plans strategies tamiflu united states joint supervisory committee evaluate roches overall commercial plans tamiflu global basis committees consists representatives roche us amendment also option provide specialized sales force supplement roches us marketing efforts tamiflu md anderson cancer center entered agreement md anderson cancer center relating hepsera connection agreement paid upfront license fee required pay md anderson cancer center percentage net sales based upon sales hepsera institute organic chemistry biochemistry academy sciences czech republic rega stichting iocbrega entered agreements iocbrega relating certain nucleotide compounds discovered two institutions agreements received exclusive right manufacture use sell nucleotide compounds obligated pay iocbrega percentage net sales received sales products containing patented compounds subject minimum royalty payments products covered table contents original agreement included vistide hepsera viread december agreements iocbrega amended provide reduced royalty rate future sales product incorporating adefovir active ingredient hepsera tenofovir active ingredient viread truvada return upfront payment us upon signing amendment august agreements iocbrega amended include truvada future fixeddose combination products contain licensed technology iocbrega agreed waive right royalty sales truvada viread developing countries sell products profit access program sales atripla distributed merck developing countries august executed amendment iocbrega sets forth royalty obligations sales tenofovir certain upper lower middle income countries sales tenofovir manufactured indian generic companies certain specified developing countries including india astellas pharma inc astellas entered agreement astellas successor fujisawa usa inc related rights market ambisome agreement amended astellas responsible promotion ambisome united states astellas sole marketing rights ambisome canada exclusive marketing rights ambisome rest world subject obligation pay royalties astellas connection sales significant markets asia including china india japan republic korea taiwan astellas collects payments sale ambisome united states canada entitled receive royalties based specified percentage astellass gross profits sale ambisome united states canada university license equity holdings inc ulehi ongoing collaborative arrangement ulehi successor university technology corporation predecessor university research corporation technology holding company university colorado boulder relating identification aptamers oligonucleotides diagnostic therapeutic applications using selex technology arrangement ulehi granted us present future rights inventions covered patents patent applications selex technology improvements selex technology makes discovers oligonucleotides molecules makes using selex technology computer software related selex technology required pay ulehi royalties based revenues generated sales products derived using selex technology including revenues based license agreement osi relating macugen may ulehi assigned part royalty income capital royalty partners lp pursuant consent agreement signed connection assignment pay part royalty obligation related selex process patent capital royalty partners lp developing world collaborations december established gilead access program pursuant agreed make truvada viread available noprofit prices developing countries africa caribbean latin america southeast asia take steps ensure viread truvada sold program used serve patients developing world diverted markets utilizing different trade dress us european tablets following list representative developing world collaborations international partnership microbicides ipm conrad december entered agreement granted rights ipm conrad cooperating agency us agency international development usaid committed improving reproductive health expanding contraceptive choices women men develop manufacture proven efficacious arrange distribution resourcelimited countries tenofovir microbicide prevent infection hiv table contents merck august entered agreement affiliate merck pursuant working merck provide low cost atripla hivinfected patients developing countries africa caribbean latin america southeast asia utilizing different trade dress us european tablets agreement manufacture atripla using efavirenz supplied merck merck handle distribution product countries covered agreement generic licenses entered nonexclusive license agreements eleven indian generic manufacturers granting rights produce distribute generic versions tenofovir lowincome countries around world included india many lowincome countries gilead access program agreements require generic manufacturers meet certain national international regulatory standards include technology transfer enable expeditious production large volumes high quality generic versions tenofovir addition agreements allow manufacture commercial quantities active pharmaceutical ingredient finished product aspen pharmacare october entered nonexclusive manufacture distribution agreement aspen pharmacare providing manufacture distribution viread truvada certain developing world countries included gilead access program bill melinda gates foundation gates foundation family health international fhi december entered agreement gates foundation fhi provide viread fhis multinational clinical trial evaluating vireads effectiveness method reducing risk hiv infection among sexually active adults regularly exposed hiv clinical trials conducted fhi funded million grant gates foundation clinical trials completed march institute one world health january entered agreement institute one world health pursuant provide ambisome cost phase clinical trial evaluating ambisome treatment visceral leishmaniasis paromomycin india greatest global burden visceral leishmaniasis exists clinical trial conducted institute one world health partnership world health organization dart study november entered collaborative agreement medical research council mrc united kingdom boehringer ingelheim gmbh gsk connection fiveyear clinical study conducted mrc antiretroviral hiv therapy africa trial called dart study development antiretroviral therapy aimed studying clinical versus laboratory monitoring practices structured treatment interruptions continuous antiretroviral therapy adults hiv infection subsaharan africa provide viread cost dart study table contents research collaborations following list representative research collaborations research collaboration partner program area year signing japan tobacco gs also known jtk treatment hiv achillion gs also known ach related compounds treatment hcv genelabs nucleoside rna polymerase inhibitors treatment hcv novartis vaccines small molecule therapeutics certain hcv drug targets glaxosmithkline ambrisentan treatment certain hypertensive conditions novartis institutes novel compounds treatment cardiovascular disease abbott laboratories ambrisentan darusentan treatment certain hypertensive conditions university texas novel compounds treatment cardiac hypertrophy heart failure japan tobacco march entered licensing agreement japan tobacco japan tobacco granted us exclusive rights develop commercialize novel hiv integrase inhibitor gs also known jtk countries world excluding japan japan tobacco would retain rights terms agreement paid upfront license fee well milestone payment additionally obligated make additional cash payments upon achievement certain milestones well pay royalties based future net product sales territories may market drug achillion pharmaceuticals inc achillion november entered exclusive license collaboration agreement achillion pursuant agreement granted worldwide rights research development commercialization certain small molecule hcv replication inhibitors involving hcv protease treatment hepatitis c collaboration achillion obligated continue development inhibitor compounds according mutually agreed upon development plan completion proofofconcept clinical study hcvinfected patients costs incurred achieve proofofconcept shared equally achillion us contractually agreed upon budget following proofofconcept study obligated assume full responsibilities incur costs associated development commercialization compounds warranting development achillion option participate us commercialization efforts future products arising collaboration conjunction signing collaboration paid upfront license fee made certain investments achillions equity also agreed make payments achillion upon achievement certain milestones outlined agreement pay royalties future net sales products arising collaboration december achillion began dosing hcv infected patients phase clinical study gs also known ach treatment hepatitis c february based preliminary data phase b study companies decided discontinue development gs genelabs technologies inc genelabs september entered license research collaboration agreement genelabs research develop commercialize certain genelabss novel nucleoside inhibitors hcv polymerase treatment chronic infection caused hcv conjunction signing agreement paid upfront license fee initial term three years term may extended additional year option genelabs obligated table contents lead research efforts agreed provide annual research payments fund fulltime equivalents lead development commercialization activities obligated make additional payments upon achievement certain milestones pay royalties future net sales selected compounds developed approved relation collaboration novartis vaccines diagnostics inc novartis vaccines august entered nonexclusive licensing agreement novartis vaccines successor chiron corporation research development commercialization small molecule therapeutics selected hcv drug targets agreement received nonexclusive rights use novartis vacciness hcv technology develop commercialize products treatment hcv terms agreement paid novartis vaccines upfront license fee agreed make additional payments certain clinical regulatory contractually determined milestones met additionally obligated make royalty payments event product developed using licensed technology glaxosmithkline gsk march myogen acquired us november entered license agreement gsk gsk received exclusive sublicense rights ambrisentan certain hypertensive conditions territories outside united states license agreement myogen received upfront payment subject achievement specific milestones eligible receive additional milestone payments addition receive stepped royalties based net commercial sales ambrisentan gsk territory gsk option negotiate us exclusive sublicense additional therapeutic uses ambrisentan gsk territory term license agreement agreement continue conduct bear expense clinical development activities believe required obtain maintain regulatory approvals ambrisentan united states canada european economic area party may conduct additional development activities territory expense parties may agree jointly develop ambrisentan new indications licensed field party pay share external costs associated joint development novartis institutes biomedical research inc novartis institutes october myogen entered research collaboration novartis institutes discovery development novel drugs treatment cardiovascular disease novartis institutes provide research funding us exchange rights license compounds developed collaboration may collaboration expanded include myogens histone deacetylase inhibitor hdaci program novartis institutes exclusive option discoveries relevant field limited exceptions may relating hdaci product candidates october relating product candidates hdaci product candidates upon execution license product candidate novartis institutes obligated fund development product candidate make payments us upon achievement certain milestones pay us royalties sales product successfully commercialized date novartis institutes licensed drug targets compounds terms collaboration abbott laboratories inc abbott october myogen entered license agreement abbott successfully develop ambrisentan pah required make additional milestone payments well pay royalties based net sales ambrisentan fail commercialize ambrisentan certain markets abbott may market product affected markets paying us royalty sales december filed nda fda treatment pah ambrisentan march myogen licensed rights commercialize ambrisentan territories outside united states gsk june myogen entered exclusive worldwide license agreement abbott develop commercialize darusentan conditions except oncology obligated make future milestone payments well pay royalties based net sales successfully commercialize drug indication commercialize darusentan certain markets abbott may market product affected markets paying us royalty sales darusentan table contents currently studied clinical trials treatment patients resistant hypertension university texas system december myogen entered license agreement university texas system providing us exclusive rights certain patents technology related cardiac hypertrophy heart failure concurrently entered sponsored research agreement university fund research cardiac hypertrophy heart failure university texas southwestern medical center agreement rights inventions arising sponsored research obligated pay future annual fees beginning first year following termination sponsored research agreement percentage sublicense revenue royalties based upon net sales additionally obligated make milestone payments drugs developed licensed technology january myogen entered second license agreement amended february related sponsored research agreement university texas system agreements received exclusive rights certain patents technology relating cardiac hypertrophy heart disease heart failure including inventions arise conduct sponsored research obligation pay milestone payments plus percentage sublicense revenue royalties based upon percentage net sales sponsored research agreement entered concurrently license agreement obligated make annual payments university march research development addition entering collaborations companies universities medical research institutions seek add existing portfolio products internal discovery clinical development programs active licensing product acquisition strategy acquisitions myogen corus year research scientists foster city san dimas california durham north carolina seattle washington westminster colorado engaged discovery development new molecules technologies hope lead new medicines novel formulations existing drugs internal research focused discovery development treatments diseases following areas hiv february announced completed phase study gs novel hiv integrase inhibitor licensed japan tobacco clinical study met primary endpoint noninferiority viral load reduction hivpositive patients begun designing phase study pending discussion fda may commence second quarter integrase inhibitors represent relatively new class compounds long history clinical research development therefore may face challenges clinical trial protocol design trial enrollment results clinical trials involving integrase inhibitors may less predictable drug candidates treatment hiv hepatitis hbv june completed enrollment two phase studies comparing efficacy safety tenofovir disoproxil fumarate active pharmaceutical ingredient viread versus hepsera patients infected hepatitis b anticipate data studies second half pending positive outcome studies anticipate filing regulatory approval tenofovir disoproxil fumarate treatment hepatitis b united states european union prior end table contents hcv december collaboration partner achillion began dosing patients gs also known ach small molecule inhibitor hcv phase viral dynamic study goal trial evaluate pharmacokinetics tolerability safety multiple escalating doses gs hcvinfected patients february based preliminary data study companies decided discontinue development gs treatment hcv infection fourth quarter began dosing hcvinfected patients phase study gs nonnucleoside polymerase inhibitor anticipate safety efficacy data study second quarter respiratory cardiopulmonary diseases expanded research development focus include respiratory cardiopulmonary diseases acquisition corus august acquisition myogen november december announced phase aircf study aztreonam lysine inhalation treatment people cf pulmonary pseudomonas aeruginosa met primary efficacy endpoint time need inhaled intravenous antibiotics assessed onset common symptoms predictive pulmonary exacerbation completed enrollment second phase study january expect data study midyear pending positive outcome second study anticipate file regulatory approval aztreonam lysine inhalation treatment cf united states second half addition aztreonam lysine inhalation exploring inhaled compounds treatment respiratory infections december also completed submission nda fda marketing approval ambrisentan oncedaily treatment pah february fda granted us priority review status nda marketing approval ambrisentan established target review date june june initiated phase clinical trials evaluate darusentan patients resistant hypertension study enrolled slowly evaluating certain modifications studys protocol following discussion regulatory authorities may implemented increase enrollment rate study also intend begin enrollment second phase study year addition also research collaboration agreement novartis institutes focused identification diseasemodifying drugs treatment chronic heart failure related cardiovascular disorders total research development expenses million compared million million patents proprietary rights patents proprietary rights important business properly designed enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection united states internationally file additional patent applications appropriate cover improvements compounds products technology also rely trade secrets internal knowhow technological innovations agreements third parties develop maintain protect competitive position ability competitive depend success strategy number us foreign patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents table contents following table shows actual estimated expiration dates united states europe primary patents patents may issue pending applications cover compounds marketed products us european patent patent products expiration expiration daunoxome vistide hepsera ambisome tamiflu macugen viread emtriva truvada atripla patents covering truvada viread atripla emtriva hepsera vistide held third parties acquired exclusive rights patents agreements parties see commercial collaborations patents cover active ingredients ambisome instead hold patents liposomal formulations compound also protect formulations trade secrets although patent filings covering forms adefovir dipivoxil active ingredient hepsera china certain countries asia applications pending various countries asia including china relate specific forms formulations hepsera asia major market impacted hepatitis b indication hepsera developed addition flolans patent held third party market exclusivity protection expired result one generic pharmaceutical companies may launch attempt launch generic version flolan united states thereafter may obtain patents certain products many years obtain marketing approval products patents limited life may begin run prior commercial sale related product commercial value patent may limited however may able apply patent term extensions example extensions patents vistide granted united states number european countries compensating part delays obtaining marketing approval similar patent term extensions may available products developing certain obtain also important infringe patents proprietary rights others violate agreements grant proprietary rights us infringe patents violate agreements could prevented developing selling products using processes covered patents agreements could required obtain license third party allowing us use technology certain required could obtain license thirdparty technology could obtain one reasonable cost able obtain required license could adversely affected patent applications confidential least period time patent issued may know competitors filed patent applications technology covered pending applications first invent technology subject patent applications competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete patents competitors file patent applications covering technology may participate interference proceedings litigation determine right patent litigation interference proceedings expensive even ultimately successful patents relating pharmaceutical biopharmaceutical biotechnology products compounds processes cover existing compounds products processes likely file future always provide complete adequate protection future litigation reexamination table contents proceedings regarding enforcement validity existing patents future patents could invalidate patents substantially reduce protection addition pending patent applications patent applications filed collaborative partners may result issuance patents may result patents provide adequate protection result may able prevent third parties developing compounds products developed developing addition certain countries africa asia including china permit enforcement patents manufacturers able sell generic versions products countries part approval process products fda determined products would granted exclusivity period manufacturers applications approval generic versions product granted generic manufacturers often wait challenge patents protecting products granted exclusivity one year prior end exclusivity period time time received notices manufacturers indicating intend import chemical intermediates possibly use making products therefore possible generic manufacturers considering attempts seek fda approval similar identical drug abbreviated new drug application application form typically used manufacturers seeking approval generic drug patents subject challenges may need spend significant resources defend challenges may able defend patents successfully also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology covered patents instead protected trade secret protect rights mainly confidentiality agreements corporate partners employees consultants vendors agreements provide confidential information developed made known individual course relationship us kept confidential used disclosed third parties except specified circumstances case employees agreements provide inventions made individual employed us exclusive property certain parties comply confidentiality agreements adequate remedies breach trade secrets otherwise become known independently discovered competitors research development agreements inventions discovered certain cases become jointly owned us corporate partner cases become exclusive property one us difficult determine owns particular invention disputes could arise regarding inventions manufacturing raw materials antiviral products contract third parties manufacture antiviral products clinical commercial purposes including truvada viread atripla emtriva hepsera vistide tamiflu historically manufactured antiviral products commercialscale however november acquired raylo chemicals inc raylo subsidiary germanybased specialty chemicals company degussa ag raylos operations encompassed custom manufacturing active pharmaceutical ingredients advanced intermediates pharmaceutical biopharmaceutical industries result raylo acquisition ability produce tenofovir disoproxil fumarate emtricitabine edmonton alberta canada facility intend utilize site process research scaleup clinical development candidates manufacture active pharmaceutical ingredients investigational commercial products chemical development activities improve existing commercial manufacturing processes use multiple thirdparty contract manufacturers manufacture tenofovir disoproxil fumarate active pharmaceutical ingredient viread component truvada atripla emtricitabine active pharmaceutical ingredient emtriva adefovir dipivoxil active pharmaceutical ingredient hepsera cidofovir active pharmaceutical ingredient vistide thirdparty contract manufacturers manufacturing active pharmaceutical ingredient table contents truvada viread atripla hepsera tableting performed thirdparty contract manufacturers manufacturers qualified approved supply product united states european union markets emtriva capsulation also completed thirdparty contract manufacturers use single thirdparty manufacturer supply vistide completed installation additional filling packaging capabilities facilities san dimas california dublin ireland san dimas site received regulatory approval united states approval european union expected first half dublin site received regulatory approval united states european union regulatory approvals allow us fill package drug product truvada viread atripla emtriva hepsera finished forms roche third parties responsible manufacturing tamiflu agreement roche joint manufacturing committee composed representatives roche us opportunity review roches existing manufacturing capacity tamiflu global plans manufacturing tamiflu future antiviral products continue consider developing additional manufacturing capabilities establishing additional thirdparty suppliers manufacture sufficient quantities product candidates undertake clinical trials manufacture sufficient quantities product approved commercial sale unable develop manufacturing capabilities internally contract large scale manufacturing third parties acceptable terms future antiviral products ability conduct large scale clinical trials meet customer demand commercial products would adversely affected believe technology use manufacture products proprietary antiviral products disclosed necessary aspects technology contract manufacturers enable manufacture products us agreements manufacturers intended restrict using revealing technology certain manufacturers comply restrictions addition manufacturers could develop technology related work perform us may need manufacture products could required enter agreement manufacturer wanted use technology allow another manufacturer use technology manufacturer could refuse allow us use technology could demand terms use technology acceptable ambisome manufacture ambisome commercial quantities facilities san dimas california medicines control agency united kingdom fda approved commercial production ambisome facilities import ambisome european union manufacturing facility dublin ireland perform quality control testing final labeling packaging distribution european union elsewhere use commercially available materials equipment manufacture products currently obtain cholesterol use manufacture ambisome single approved supplier ambisome sold freezedried product currently freezedry fill ambisome san dimas facility also use third party freezedry fill additional product needed given current projections ambisome demand believe sufficient production capacity meet future demand also option installing additional freezedrying capacity san dimas additional requirements become necessary macugen manufacture macugen commercial quantities fda approved facilities san dimas manufacturing agreement osi use commercially available materials equipment produce fill table contents product currently osi provides raw materials used manufacture macugen including pegaptanib sodium active pharmaceutical ingredient macugen single approved suppliers contracted osi given osis current projections macugen demand believe sufficient production capacity meet future demand flolan gsk affiliates third parties exclusive right manufacture flolan distribution us united states terms distribution supply agreement gsk seasonal operations backlog worldwide product sales reflect significant degree seasonality however royalty revenue represented total revenues tamiflu royalties comprised significant portion affected seasonality royalty revenue recognize roches sale tamiflu impacted severity associated flu seasons product delivery response avian influenza pandemic threat part operate markets characterized short lead times absence significant backlogs believe backlog information material business whole government regulation operations activities subject extensive regulation numerous government authorities united states countries united states drugs subject rigorous fda regulation federal food drug cosmetic act federal state statutes regulations govern testing manufacture safety effectiveness labeling storage record keeping approval advertising promotion products result regulations product development product approval processes expensive time consuming fda must approve drug sold united states general process approval follows preclinical testing test drug candidate humans must study drug laboratory experiments animals generate data support drugs potential benefits safety submit data fda investigational new drug ind application seeking approval test compound humans clinical trials fda accepts ind application study drug human clinical trials determine drug safe effective clinical trials involve three separate phases often overlap take many years expensive three phases subject considerable regulation follows phase drug given small number healthy human control subjects patients suffering indicated disease test safety dose tolerance pharmacokinetics metabolism distribution excretion phase drug given limited patient population determine effect drug treating disease best dose drug possible side effects safety risks drug uncommon drug appears promising phase clinical trials fail rigorous phase clinical trials table contents phase compound appears effective safe phase clinical trials phase clinical trials commenced confirm results phase clinical trials longterm involve significantly larger population conducted numerous sites different geographic regions carefully designed provide reliable conclusive data regarding safety benefits drug uncommon drug appears promising phase clinical trials fail rigorous phase clinical trials fda approval process believe data phase clinical trials shows adequate level safety effectiveness file nda fda seeking approval sell drug particular use fda review nda often hold public hearing independent advisory committee expert advisors asks additional questions makes recommendations regarding drug committee makes recommendation fda binding generally followed fda fda agrees compound met required level safety effectiveness particular use allow us sell drug united states use unusual however fda reject application believes drug safe enough effective enough believe data submitted reliable conclusive point process development drug could stopped number reasons including safety concerns lack treatment benefit certain clinical trials currently conducting conduct future completed successfully within specified time period may choose fda may require us delay suspend clinical trials time appears patients exposed unacceptable health risk drug candidate appear sufficient treatment benefit fda may also require phase nonregistrational studies explore scientific questions characterize safety efficacy commercial use drug fda may also require us provide additional data information improve manufacturing processes procedures facilities may require extensive postmarketing testing surveillance monitor safety benefits product candidates determines nda contain adequate evidence safety benefits drug addition even fda approves drug could limit uses drug fda withdraw approvals believe complying regulatory standards problems uncovered occur approval addition obtaining fda approval drug obtain fda approval manufacturing facilities drug sell including companies manufacture drugs us facilities subject periodic inspections fda fda must also approve foreign establishments manufacture products sold united states facilities subject periodic regulatory inspection manufacturing facilities located california including san dimas foster city facilities also must licensed state california compliance local regulatory requirements manufacturing facilities located canada including edmonton alberta facility also must obtain local licenses permits compliance local regulatory requirements drugs treat serious lifethreatening diseases conditions adequately addressed existing drugs development program designed address unmet medical need may designated fast track candidates fda may eligible accelerated priority review drugs treatment hiv designated use presidents emergency plan aids relief pepfar may also qualify expedited priority review viread truvada atripla received accelerated approval priority reviews drugs receiving accelerated approval must monitored postmarketing clinical trials order confirm safety benefits drug also subject federal state local regulations regarding workplace safety protection environment use hazardous materials chemicals viruses various radioactive compounds table contents research development activities eliminate risk accidental contamination injury materials misuse accidents involving materials could lead significant litigation fines penalties drugs also subject extensive regulation outside united states european union centralized approval procedure authorizes marketing product countries european union includes major countries europe procedure used approval one country european union used obtain approval another country european union two simplified application processes mutual recognition procedure decentralized procedure rely principle mutual recognition receiving regulatory approval european registration procedures pricing reimbursement approvals also required countries pricing reimbursement successful commercialization depends part availability governmental thirdparty payor reimbursement cost products government authorities thirdparty payors increasingly challenging price medical products services business may adversely affected increase global pricing pressures united states number legislative regulatory changes healthcare system could impact pricing products medicare prescription drug improvement modernization act medicare beneficiaries able elect coverage prescription drugs medicare part various entities providing coverage attempt negotiate price concessions pharmaceutical manufacturers may increase pressure lower prescription drug prices may limit drug access prescription drug program began january although benefited patients transitioning medicaid medicare part potentially detrimental impact longer term new law business relates product united states yet clear us impact depend part specific decisions regarding level coverage provided therapeutic categories products included terms coverage provided extent preference given selected products category medicare patients pay coinsurance may influence products recommended physicians selected patients changes medicare reimbursement could negative effect revenue federal medicare proposals along state medicaid drug payment changes healthcare reforms could also lower payment products addition extent private insurers blue cross blue shield managed care programs follow medicaid coverage payment developments adverse effects lower medicare payment may magnified private insurers adopting lower payment schedules additionally states enacted health care reform legislation federal state developments possible europe success viread truvada emtriva hepsera ambisome tamiflu well atripla marketing approval obtained european union depend largely obtaining maintaining government reimbursement many european countries patients use prescription drugs reimbursed governments even reimbursement available reimbursement policies may adversely affect ability sell products profitable basis example europe many international markets governments control prices prescription pharmaceuticals expect prices prescription pharmaceuticals decline life product volumes increase new drugs come market may face significant price decreases products across much europe believe continue foreseeable future governments struggle escalating health care spending result pricing practices may become difficult maintain historic levels profitability achieve expected rates growth health care fraud abuse laws subject various federal state laws pertaining health care fraud abuse including antikickback laws false claims laws antikickback laws make illegal prescription drug manufacturer table contents solicit offer receive pay remuneration exchange induce referral business including purchase prescription particular drug due breadth statutory provisions increasing attention given law enforcement authorities possible certain practices may challenged antikickback similar laws false claims laws prohibit anyone knowingly willingly presenting causing presented payment thirdparty payors including medicare medicaid claims reimbursed drugs services false fraudulent claims items services provided claimed claims medically unnecessary items services sales marketing activities may subject scrutiny laws violations fraud abuse laws may punishable criminal andor civil sanctions including fines civil monetary penalties well possibility exclusion federal health care programs including medicare medicaid government allege convict us violating laws could material adverse effect results operations november received subpoena united states attorneys office san francisco requesting documents regarding marketing medical education programs truvada viread emtriva complying us attorneys subpoena intend cooperate related government investigation compulsory licenses governments developing countries could require grant compulsory licenses allow competitors manufacture sell versions products thereby reducing product sales example past certain offices government brazil expressed concern affordability hiv products declared considering issuing compulsory licenses permit manufacture otherwise patented products hiv infection including viread result discussions brazilian government reached agreement brazilian health ministry may reduce price viread brazil approximately addition concerns cost availability tamiflu fear grows potential avian flu pandemic generated international discussions potential compulsory licensing tamiflu patents example aware canadian government considering measures would allow canadian manufacturers manufacture sell active ingredient tamiflu canada certain countries furthermore roche may issue voluntary licenses permit thirdparty manufacturing tamiflu example roche granted sublicense shanghai pharmaceutical group co ltd china sublicense indias hetero drugs limited india certain developing countries one compulsory licenses issued permitting generic manufacturing override tamiflu patents roche issue additional voluntary licenses permit thirdparty manufacturing tamiflu developments could reduce royalties received roches sales tamiflu certain countries permit enforcement patents manufacturers able sell generic versions products countries compulsory licenses generic versions products could significantly reduce sales adversely affect results operations particularly sales generic versions products imported territories existing commercial sales employees january approximately fulltime employees believe good relations employees environment seek comply applicable statutory administrative requirements concerning environmental quality made continue make expenditures environmental compliance protection expenditures compliance environmental laws expected material effect capital expenditures results operations competitive position table contents information subject information requirements exchange act therefore file periodic reports proxy statements information sec reports proxy statements information may obtained visiting public reference room sec f street ne washington dc calling sec sec sending electronic message sec publicinfosecgov sending fax sec addition sec maintains website wwwsecgov contains reports proxy information statements information regarding issuers file electronically mailing address headquarters lakeside drive foster city california telephone number location website wwwgileadcom link investors section website sec filings financial information section make available following filings soon reasonably practicable electronically filed furnished sec annual reports quarterly reports form q current reports form k amendments reports filed furnished pursuant section exchange act filings available free charge upon request item risk factors evaluating business carefully consider following risks addition information annual report following risks could materially adversely affect business results operations financial condition note factors investors permitted private securities litigation reform act possible predict identify factors therefore consider risks complete statement potential risks uncertainties face substantially revenues derived sales limited number products unable maintain continue increasing sales hiv products results operations may adversely affected currently dependent sales hiv products especially truvada viread support existing operations hiv products exclusively nucleoside class antiviral therapeutics treatment paradigm hiv change causing nucleosidebased therapeutics fall favor unable continue increasing hiv product sales results operations would likely suffer would likely need scale back operations including spending research development efforts hiv product sales year ended december billion approximately total revenues sales truvada viread accounted respectively total hiv product sales may able continue growth rate sales hiv products reasons stated risk factor section particular following reasons hiv products used longer period time many patients combination products additional studies conducted new issues respect safety resistance interactions drugs may arise could cause us provide additional warnings labels narrow approved indications halt sales product could reduce revenues product matures private insurers government reimbursers often reduce amount reimburse patients products increases pressure us reduce prices large part market hiv products consists patients already taking hiv drugs successful encouraging physicians change patients regimens include hiv products sales hiv products limited generic hiv products introduced major markets ability maintain pricing may affected table contents fail commercialize new products expand indications existing products prospects future revenues stock price may adversely affected introduce new products increase revenues existing products able increase maintain total revenues new product commercialization effort face risks outlined section fail increase sales products bring new products market may able increase revenues expand research development efforts although joint venture bms launched single tablet regimen truvada sustiva tradenamed atripla july united states physicians may reluctant prescribe atripla fail see advantages single tablet regimen antiretrovirals result may able increase revenues hiv products addition product sales atripla may increase expense product sales component products overall total revenues may increase launch atripla furthermore marketing authorization application submitted bms merck us october seeking approval atripla european union may granted timely basis face significant competition face significant competition businesses substantially greater resources addition competitors products operated fields compete longer hiv products compete primarily products gsk markets fixeddose combination products compete truvada atripla ambisome encountering significant competition new products produced merck pfizer addition aware reports least three lipid formulations claim similarity ambisome becoming available outside united states including anticipated entry one formulation greece formulations may reduce market demand ambisome furthermore manufacture lipid formulations amphotericin b complex formulations found unsafe sales ambisome may negatively impacted association hepsera encountered increased competition launch bmss baraclude entecavir launch novartisidenixs tyzeka telbivudine united states companies substantially greater resources may significantly impede ability successful antiviral products ambisome addition developing aztreonam lysine inhalation treatment bacterial infections patients cf ambrisentan treatment pah approved aztreonam lysine would compete tobi tobramycin inhalation marketed novartis ambrisentan would compete directly actelion ltds tracleer bosentan indirectly pah products united therapeutics corporation pfizer significant safety issues arise marketed products product candidates future sales may reduced would adversely affect results operations data support marketing approvals products form basis safety warnings product labels obtained controlled clinical trials limited duration cases limited postapproval use products including truvada viread atripla emtriva ambisome hepsera used longer periods time many patients taking numerous medicines many underlying health problems expect continue find new issues safety resistance drug interaction issues may require us provide additional warnings contraindications labels narrow approved indications could reduce market acceptance products safety efficacy studies viread emtriva dosed separate products ongoing underway longer period time safety efficacy studies truvada viread emtriva together also underway also conducting similar studies atripla viread emtriva sustiva together serious safety resistance interaction issues arise marketed products sales products could limited halted us regulatory authorities addition following acquisition myogen developing new product candidates darusentan ambrisentan different safety profile current marketed products new product table contents candidates developed may prove susceptible safety resistance drug interaction issues experienced past safety issues arise product candidates clinical development programs may limited halted us regulatory authorities product candidates may never become marketable products operations depend compliance complex fda comparable international regulations failure obtain broad approvals timely basis achieve continued compliance could delay halt commercialization products products develop must approved marketing sale regulatory authorities approved subject extensive regulation fda comparable regulatory agencies countries continuing clinical trials truvada viread atripla emtriva ambisome hepsera currently approved additional uses anticipate file marketing approval additional countries additional products next several years products may fail receive marketing approval timely basis addition marketed products manufacture sell products subject extensive continued regulation review discovery previously unknown problems marketed products problems manufacturing promotional activities may result restrictions products including withdrawal products market fail comply applicable regulatory requirements could subject penalties including fines suspensions regulatory approvals product recalls seizure products criminal prosecution results clinical trials uncertain may support continued development product pipeline would adversely affect prospects future revenue growth required demonstrate safety effectiveness products develop intended use extensive preclinical studies clinical trials results preclinical early clinical studies always accurately predict results later largescale clinical trials even successfully completed largescale clinical trials may result marketable products products development fails achieve primary endpoint clinical trials safety issues arise commercialization drug candidate could delayed halted addition clinical trials involving commercial products could raise new safety issues existing products could turn reduce revenues due reliance thirdparty contract research organizations conduct clinical trials unable directly control timing conduct expense quality clinical trials extensively outsource clinical trial activities usually perform small portion startup activities inhouse rely independent thirdparty contract research organizations cros control perform clinical studies including document preparation site identification screening preparation prestudy visits training program management bioanalytical analysis dispute disruption relationship cros clinical trials may delayed moreover regulatory submissions rely quality validity clinical work performed thirdparty cros cros processes methodologies results determined invalid inadequate clinical data results related regulatory approvals could adversely impacted february advised fda discovered certain irregularities inspection bioanalytical analyses conducted various organizations one thirdparty cros period review cro performed bioanalytical analyses studies certain products know whether investigation involves impact clinical data results related regulatory approvals table contents may able successfully integrate existing business businesses corus pharma inc raylo chemicals inc myogen inc integrating businesses existing business complex timeconsuming process recently corus raylo myogen operated independently us business corporate culture locations employees systems result acquisitions operate existing business along businesses corus raylo myogen one combined organization utilizing common information communication systems operating procedures financial controls human resources practices including benefits training professional development programs may substantial difficulties costs delays involved integration companies us integration us company assets may time time acquire failure successfully integrate companies us assets companies may acquire may material adverse effect business financial condition results operations remaining efforts completion coruss myogens research development projects primarily consist clinical trials cost length success extremely difficult predict obtaining necessary regulatory approvals numerous risks uncertainties exist could prevent completion development including ability enroll patients clinical trials possibility unfavorable results clinical trials risk failing obtain fda regulatory body approvals feedback regulatory authorities results clinical trials might require modifications delays later stage clinical trials additional trials performed certain aztreonam lysine cf purchased corus ambrisentan pah purchased myogen pending fda review approved united states countries outside united states whether marketing approvals significant limitations use future discussions regulatory agencies determine amount data needed timelines review may differ materially current projections acquired product candidates development may never successfully commercialized result may make strategic decision discontinue development product candidates example believe commercialization difficult relative opportunities pipeline either programs completed timely basis prospects future revenue growth may adversely impacted manufacturing problems could delay product shipments regulatory approvals may adversely affect results operations depend third parties perform manufacturing activities effectively timely basis truvada viread atripla emtriva hepsera vistide manufacturing process pharmaceutical products highly regulated regulators may shut manufacturing facilities believe comply regulations manufacturers subject fdas current good manufacturing practices extensive regulations governing manufacturing processes stability testing record keeping quality standards similar regulations effect countries manufacturing operations also subject routine inspections regulatory agencies additionally thirdparty manufacturers independent entities subject unique operational financial risks control extent risks materialize affect performance obligations us may adversely affect financial results also depend thirdparty manufacturers manufacture truvada viread atripla made available physicians treatment programs noprofit prices developing countries gilead access program rely third parties manufacture active pharmaceutical ingredient final drug product clinical commercial purposes addition roche either third parties responsible manufacturing tamiflu thirdparty manufacturers fail perform required could impair ability deliver products timely basis receive royalties cause table contents delays clinical trials applications regulatory approval events could harm competitive position financial results may able manufacture ambisome macugen meet market needs event business interruptions san dimas facility manufacture ambisome fill finish macugen facilities san dimas california formulation manufacturing facilities united states event natural disaster including earthquake equipment failure strike difficulty may unable replace manufacturing capacity timely manner may unable manufacture ambisome macugen meet market needs ability successfully manufacture commercialize aztreonam lysine approved depend upon ability continue manufacture multiproduct facility aztreonam lysine monolactam gramnegative antibiotic currently plan manufacture third parties multiproduct manufacturing facility historically fda permitted manufacture monolactams multi product manufacturing facilities however assurances fda continue allow practice currently singleproduct facility dedicated manufacture aztreonam lysine engaged contract manufacturer singleproduct facility aztreonam lysine fda prohibits manufacture monolactam antibiotics like aztreonam lysine multiproduct manufacturing facilities future may able procure singleproduct manufacturing facility timely manner would adversely affect commercial supplies aztreonam lysine anticipated financial results attributable product approved may able obtain materials supplies necessary manufacture sell products could limit ability generate revenues materials utilize operations made one facility example depend single supplier high quality cholesterol used manufacture ambisome suppliers key components materials must named nda filed fda product significant delays occur qualification new supplier required delivery material suppliers interrupted reason may unable ship truvada viread atripla emtriva hepsera ambisome vistide supply products development clinical trials addition aztreonam lysine inhalation developing administered lungs patients device made single supplier currently working supplier prepare commercial launch aztreonam lysine inhalation regulatory approval obtained sufficient quantities device available time commercial launch following launch encounter problems relationship supplier commercial launch aztreonam lysine inhalation could delayed anticipated contribution aztreonam lysine financial results could adversely effected table contents depend relationships companies sales marketing performance revenues failure maintain relationships poor performance companies disputes companies could negatively impact business rely number significant collaborative relationships major pharmaceutical companies sales marketing performance certain territories include collaborations astellas created merger yamanouchi pharmaceutical co ltd fujisawa pharmaceutical co ltd sumitomo ambisome gsk hepsera roche tamiflu pfizer vistide osi pfizer macugen japan tobacco viread truvada emtriva joint venture bms atripla many countries rely international distributors sales truvada viread emtriva ambisome hepsera relationships also involve clinical development products partners reliance collaborative relationships poses number risks including risk able control resources corporate partners devote programs products disputes may arise respect ownership rights technology developed corporate partners disagreements corporate partners could cause delays termination research development commercialization product candidates result litigation arbitration contracts corporate partners may fail provide significant protection may fail effectively enforced one partners fails perform corporate partners considerable discretion electing whether pursue development additional products may pursue alternative technologies products either collaboration competitors corporate partners marketing rights may choose pursue competing technologies devote fewer resources marketing products products development distributors corporate partners may unable pay us given risks great deal uncertainty regarding success current future collaborative efforts efforts fail product development commercialization new products could delayed revenue existing products could decline april licensing agreement gsk gave gsk right control clinical regulatory development commercialization hepsera territories asia africa latin america include major markets hepsera china japan taiwan republic korea success hepsera territories depend almost entirely efforts gsk regard gsk promotes epivirhbvzeffix product competes hepsera consequently gsks marketing strategy hepsera may influenced promotion epivirhbvzeffix receive royalties gsk equal percentage gsks net sales hepsera well net sales gsks epivirhbvzeffix gsk fails devote sufficient resources succeed developing commercializing hepsera territories potential revenues sales hepsera territories may substantially reduced expenses associated clinical trials sales fluctuations result inventory levels held wholesalers may cause earnings fluctuate could adversely affect stock price clinical trials required regulatory approval products well clinical trials required conduct approval expensive difficult accurately predict control amount timing expenses quarter quarter uneven unexpected spending programs may cause operating results fluctuate quarter quarter table contents estimate future demand product consider shelf life inventory regularly review realizability inventory actual demand less estimated demand could required record inventory writedowns would adverse impact results operations example result review inventory realizability first fourth quarters recorded writedowns portion gilead access program inventory additional write downs inventory gilead access program may necessary demand hiv products access program countries sufficient consume existing inventories year ended december approximately product sales united states three wholesalers amerisourcebergen corp cardinal health inc mckesson corp inventory levels held wholesalers cause operating results fluctuate unexpectedly sales wholesalers match end user demand us wholesalers entered inventory management agreements may completely effective matching inventory levels end user demand make estimates determine end user demand nonretail sector united states includes government institutions correctional facilities large health maintenance organizations currently contributes approximately hiv business tends less consistent terms buying patterns often results quarter quarter fluctuations necessarily mirror growth patterns seen retail prescription data unpredictable variability roches tamiflu sales strong relationship revenue global pandemic planning also cause royalty revenues fluctuate quarter quarter success depend significant degree ability protect patents intellectual property rights domestically internationally number patents patent applications rights patents related compounds products certain issued patents enforceable provide adequate protection pending patent applications result issued patents competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete patents patent applications confidential least period time patent issued result may know competitors filed patent applications technology covered pending applications first invent technology subject patent applications competitors file patent applications covering technology may participate interference proceedings litigation determine right patent litigation interference proceedings expensive even ultimately successful part approval process products fda determined products would granted exclusivity period manufacturers applications approval products granted generic manufacturers often wait challenge patents protecting products one year prior end exclusivity period time time received notices manufacturers indicating intend import chemical intermediates possibly use making products therefore possible generic manufacturers considering attempts seek fda approval similar identical drug abbreviated new drug application application form typically used manufacturers seeking approval generic drug patents subject challenges may need spend significant resources defend challenges may able defend patents successfully success depends large part ability operate without infringing upon patents proprietary rights third parties infringe patents others may prevented commercializing products may required obtain licenses third parties may able obtain alternative technologies required license reasonable terms fail obtain licenses alternative technologies may unable develop commercialize products table contents addition use significant proprietary technology rely unpatented trade secrets proprietary knowhow protect certain aspects production technologies trade secrets may become known independently discovered competitors approximately half product sales occur outside united states currency fluctuations may cause earnings fluctuate could adversely affect stock price significant percentage product sales denominated foreign currencies primarily euro increases value us dollar foreign currencies past reduced future may reduce us dollar equivalent sales negatively impact financial condition results operations use foreign currency forward contracts hedge percentage forecasted international sales primarily denominated euro currency also hedge portion accounts receivable balances denominated foreign currencies reduces eliminate exposure currency fluctuations date sale recorded date cash collected hedging program hedges portion total exposure significant foreign exchange rate fluctuations within short period time could adversely affect results operations face credit risks european customers may adversely affect results operations european product sales government owned supported customers greece italy portugal spain subject significant payment delays due government funding reimbursement practices accounts receivable government owned supported customers countries totaled million december historically receivables tended accumulate period time settled large lump sum payments government funding became available significant changes occur reimbursement practices european governments government funding becomes unavailable may able collect amounts due us customers results operations would adversely affected product revenues could reduced imports countries products available lower prices prices products based local market economics competition sometimes differ country country sales countries relatively higher prices may reduced products imported countries lower price markets cases pharmaceutical products sold steeply discounted prices developing world reexported european countries could resold much higher prices happens products particularly truvada viread agreed make available noprofit prices countries participating gilead access program atripla merck distribute low cost hivinfected patients developing countries august agreement revenues would adversely affected addition granted nonexclusive voluntary licenses manufacture tenofovir disoproxil fumarate generic manufacturers india local indian market manufacturers export product developing world countries included gilead access program generic versions viread licenses reexported united states europe markets outside india developing world countries participating gilead access program revenues would adversely affected addition european union required permit crossborder sales allows buyers countries governmentapproved prices products relatively high purchase products legally countries sold lower prices purchases products countries sales prices relatively low resale countries sales prices relatively high may adversely impact gross margin may cause sales fluctuate quarter quarter fourth quarter seen increased instances crossborder sales europe additionally us consumers able purchase products including hiv products internet pharmacies countries substantial discounts crossborder sales could adversely affect revenues table contents countries may required grant compulsory licenses products face generic competition products number developing countries government officials groups suggested pharmaceutical companies make drugs hiv infection available low cost alternatively governments countries could require grant compulsory licenses allow competitors manufacture sell versions products thereby reducing product sales example past certain offices government brazil expressed concern affordability hiv products declared considering issuing compulsory licenses permit manufacture otherwise patented products hiv infection including viread result discussions brazilian government reached agreement brazilian health ministry may reduce price viread brazil approximately addition concerns cost availability tamiflu fear grows potential avian flu pandemic generated international discussions potential compulsory licensing tamiflu patents example aware canadian government considering measures would allow canadian manufacturers manufacture sell active ingredient tamiflu canada certain countries furthermore roche may issue voluntary licenses permit thirdparty manufacturing tamiflu example roche granted sublicense shanghai pharmaceutical group co ltd china sublicense indias hetero drugs limited india certain developing countries one compulsory licenses issued permitting generic manufacturing override tamiflu patents roche issue additional voluntary licenses permit thirdparty manufacturing tamiflu developments could reduce royalties receive roches sales tamiflu certain countries permit enforcement patents manufacturers able sell generic versions products countries compulsory licenses sales generic versions products could significantly reduce sales adversely affect results operations particularly generic versions products imported territories existing commercial sales existing products subject reimbursement government agencies third parties pharmaceutical pricing reimbursement pressures may reduce profitability successful commercialization products depends part availability governmental thirdparty payor reimbursement cost products related treatments government health administration authorities private health insurers organizations generally provide reimbursement government authorities thirdparty payors increasingly challenging price medical products services particularly innovative new products therapies resulted lower average sales prices example majority sales ambisome vistide majority sales truvada viread atripla hepsera subject reimbursement government agencies resulting significant discounts list price rebate obligations business may adversely affected increase us international pricing pressures pressures arise rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement policies pricing general europe success truvada viread emtriva hepsera ambisome tamiflu well atripla approved european union also depend largely obtaining maintaining government reimbursement many european countries patients unlikely use prescription drugs reimbursed governments addition negotiating prices governmental authorities delay commercialization twelve months also expect success products development particularly europe depend ability obtain reimbursement even reimbursement available reimbursement policies may adversely affect ability sell products profitable basis example europe many international markets governments control prices prescription pharmaceuticals expect prices prescription pharmaceuticals decline life product volumes increase new drugs come market may face significant price decreases products across much europe believe continue foreseeable future governments struggle escalating health care table contents spending result pricing practices may become difficult maintain historic levels profitability achieve expected rates growth results operations could adversely affected current future health care reforms legislative regulatory changes government prescription drug procurement reimbursement programs occur relatively frequently united states foreign jurisdictions recently significant changes federal medicare system united states could impact pricing products medicare prescription drug improvement modernization act medicare beneficiaries able elect coverage prescription drugs medicare part various entities providing coverage attempt negotiate price concessions pharmaceutical manufacturers may increase pressure lower prescription drug prices may limit drug access prescription drug program began january although benefited initially patients transitioning medicaid medicare part longer term impact new law business yet clear us impact depend part specific decisions regarding level coverage provided therapeutic categories products included terms coverage provided extent preference given selected products category medicare patients pay co insurance may influence products recommended physicians selected patients changes medicare reimbursement could negative effect revenues federal medicare proposals along state medicaid drug payment changes healthcare reforms could also lower payment products results operations could materially adversely affected reimbursement changes emerging medicare prescription drug coverage legislation addition extent private insurers blue cross blue shield managed care programs follow medicaid coverage payment developments adverse effects lower medicare payment may magnified private insurers adopting lower payment schedules additionally states enacted health care reform legislation federal state developments possible may able obtain effective patents protect technologies use competitors patents companies could require us stop using pay use required technology success depend significant degree ability obtain patents licenses patent rights preserve trade secrets operate without infringing proprietary rights others number us foreign patents patent applications rights patents related compounds products technology risk however issued patents enforceable provide adequate protection pending patent applications result issued patents patent applications confidential least period time patent issued result may know competitors filed patent applications technology covered pending applications first invent technology subject patent applications competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete patents patents cover active ingredients ambisome addition patent filings china certain asian countries covering forms adefovir dipivoxil active ingredient hepsera asia major market therapies hbv indication hepsera developed flolans patent market exclusivity protection expired result one generic pharmaceutical companies may launch attempt launch generic version flolan united states thereafter may obtain patents certain products many years marketing approval obtained products patents limited life may begin run prior commercial sale related table contents product commercial value patent may limited however may able apply patent term extensions addition certain countries africa asia including china permit enforcement patents manufacturers able sell generic versions products countries competitors may file patent applications covering technology may participate interference proceedings litigation determine right patent litigation interference proceedings expensive even ultimately successful part approval process products fda determined products would granted exclusivity period manufacturers applications approval generic versions product granted generic manufacturers often wait challenge patents protecting products granted exclusivity one year prior end exclusivity period time time received notices manufacturers indicating intend import chemical intermediates possibly use making products therefore possible generic manufacturers considering attempts seek fda approval similar identical drug abbreviated nda application form typically used manufacturers seeking approval generic drug patents subject challenges may need spend significant resources defend challenges may able defend patents successfully success depends large part ability operate without infringing upon patents proprietary rights third parties infringe patents others may prevented commercializing products may required obtain licenses third parties may able obtain alternative technologies required license reasonable terms fail obtain licenses alternative technologies may unable develop commercialize products addition use significant proprietary technology rely unpatented trade secrets proprietary knowhow protect certain aspects production technologies trade secrets may become known independently discovered competitors may face significant liability resulting products may covered insurance successful claims could materially reduce earnings testing manufacturing marketing use commercial products well products development involve substantial risk product liability claims claims may made directly consumers healthcare providers pharmaceutical companies others product liability insurance may cover successful product liability claim us could required pay amounts beyond provided insurance either could impair financial condition ability clinically test market products assumptions used determine selfinsurance levels could wrong materially impact business continually evaluate levels selfinsurance based historical claims experience demographic factors severity factors actuarial assumptions however future occurrences claims differ assumptions historical trends results operations business cash flow financial condition could materially impacted claims expenses expensive litigation government investigations may reduce earnings named defendant lawsuits regarding use average wholesale price reimbursement rates medicaid addition plaintiffs appealed dismissal class action lawsuit brought us alleging violations federal securities laws november received subpoena table contents united states attorneys office san francisco requesting documents regarding marketing medical education programs truvada viread emtriva complying us attorneys subpoena intend cooperate related government investigation outcome lawsuits lawsuits brought us investigation investigations brought us inherently uncertain adverse developments outcomes result significant monetary damages penalties injunctive relief us could significantly reduce earnings cash flows changes effective income tax rate could reduce earnings various factors may favorable unfavorable effects income tax rate factors include limited interpretations existing tax laws adoption statement financial accounting standards sfas revised sharebased payment sfas r relating accounting stock options sharebased payments changes tax laws rates mergers acquisitions future levels research development rd spending changes accounting standards future levels capital expenditures changes mix earnings various tax jurisdictions operate changes overall levels pretax earnings finalization federal state income tax audits impact income tax provision resulting abovementioned factors may significant could negative impact net income loss changes accounting stock options significantly reduced continue significantly reduce earnings subject sfas r required record additional compensation expense related stock options sharebased payments since january standard continue significant negative impact reported results operations compared results reported prior prior accounting standards stock options sharebased payments fail attract retain highly qualified personnel may unable successfully develop new product candidates conduct clinical trials commercialize product candidates future success depend large part continued ability attract retain highly qualified scientific technical management personnel well personnel expertise clinical testing governmental regulation commercialization face competition personnel companies universities public private research institutions government entities organizations competition qualified personnel biopharmaceutical field intense limited pool qualified potential employees recruit may able attract retain quality personnel acceptable terms unsuccessful recruitment retention efforts business may harmed item b unresolved staff comments applicable item properties corporate headquarters including principal executive offices commercial administrative research development facilities located foster city california location buildings lease facilities san dimas california house manufacturing warehousing research development activities addition also lease facilities durham north carolina westminster colorado seattle washington house administrative research development activities table contents european headquarters include commercial medical administrative facilities located london area united kingdom also lease facilities dublin area ireland house manufacturing distribution activities addition leased facilities house commercial medical administrative activities austria australia canada france germany greece italy portugal spain turkey united kingdom manufacturing facility edmonton alberta canada use conduct process research scaleup clinical development candidates manufacturing active pharmaceutical ingredients investigational commercial products chemical development activities improve existing commercial manufacturing processes believe existing properties including owned leased sites good condition suitable conduct business believe capital resources sufficient purchase lease construct additional facilities required meet longterm growth needs item legal proceedings information pertaining legal proceedings found heading legal proceedings item note commitments contingencies consolidated financial statements pages annual report incorporated reference herein item submission matters vote security holders matters submitted vote security holders quarter ended december table contents part ii item market registrants common equity related stockholder matters issuer purchases equity securities common stock traded nasdaq global select market symbol gild following table sets forth periods indicated high low intraday sale prices per share common stock nasdaq global select market prices represent quotations among dealers without adjustments retail markups markdowns commissions may represent prices actual transactions high low first quarter second quarter third quarter fourth quarter first quarter second quarter third quarter fourth quarter february shares common stock outstanding held approximately stockholders record paid cash dividends common stock since inception currently expect retain earnings use operation expansion business therefore anticipate paying cash dividends near future table contents performance graph following graph compares total stockholder returns past five years two indices nasdaq crsp total return index nasdaq global select market us companies labeled nasdaqus nasdaq pharmaceutical index labeled nasdaqpharmaceutical total return common stock index assumes reinvestment dividends although cash dividends never declared common stock based returns component companies weighted according capitalizations end monthly period nasdaqus tracks aggregate price performance equity securities us companies traded nasdaq global select market nasdaqpharmaceutical tracks aggregate price performance equity securities pharmaceutical companies traded nasdaq global select market common stock traded nasdaq global select market component nasdaqus nasdaqpharmaceutical indices stockholder return shown graph necessarily indicative future performance make endorse predictions future stockholder returns comparison cumulative total return investment past five years section soliciting material deemed filed sec incorporated reference filings securities act exchange act whether made date hereof irrespective general incorporation language filing shows cumulative return investment assuming investment common stock nasdaqus nasdaqpharmaceuticals indices december table contents item selected financial data gilead sciences inc selected consolidated financial data thousands except per share data year ended december consolidated statement operations data total revenues purchased inprocess research development note total costs expenses note income loss operations gain warrant note loss sale osi common stock note provision benefit income taxes notes net income loss net income loss per sharebasic note shares used per share calculationbasic note net income loss per sharediluted note shares used per share calculationdiluted note december consolidated balance sheet data cash cash equivalents marketable securities working capital total assets longterm obligations note convertible debt note retained earnings accumulated deficit total stockholders equity note note completed acquisition myogen aggregate purchase price billion billion allocated purchased inprocess research development million allocated deferred tax assets primarily related federal net operating loss tax credit carryforwards certain state amortizations million allocated goodwill million allocated net tangible assets also acquired net assets corus million million allocated purchased inprocess research development million allocated net deferred tax assets primarily related federal net table contents gilead sciences inc selected consolidated financial datacontinued operating loss tax credit carryforwards certain state amortizations million allocated net tangible assets million allocated assembled workforce recognized million royalty revenue relating resolution dispute roche also recorded tax provision benefit million related repatriation qualified foreign earnings american jobs creation act ajca recorded gain million related warrant purchase capital stock eyetech pharmaceuticals inc predecessor osi completed initial public offering completed acquisition net assets triangle aggregate purchase price million approximately million purchase price allocated purchased inprocess research development also recorded income tax benefit million related reduction valuation allowance certain net deferred tax assets sold shares common stock osi recognized loss sale marketable securities million shares partial consideration sale oncology assets note adopted sfas r modified prospective basis beginning january see notes consolidated financial statements note march september implemented twoforone stock splits form stock dividend share per share amounts periods presented restated reflect stock splits note issued billion principal amount convertible senior notes private placement entered uncollateralized million term loan facilitate cash dividend distribution part repatriation qualified foreign earnings provisions ajca note cash dividends declared paid common stock table contents item managements discussion analysis financial condition results operations following managements discussion analysis mda intended help reader understand results operations financial condition mda provided supplement read conjunction audited consolidated financial statements accompanying notes financial statements disclosures included annual report including disclosures item risk factors consolidated financial statements prepared accordance us generally accepted accounting principles presented us dollars executive summary experienced another successful year achievement several significant financial operating milestones driven continued growth sales hiv products truvada viread atripla emtriva total product sales reached billion increase coupled significant increase royalty revenue year total revenues increased billion sales hiv products billion represented increase hiv product sales primarily driven continued growth truvada especially europe truvada product sales comprised half total hiv product sales launch atripla single tablet regimen truvada bristol myers squibb companys bms sustiva efavirenz united states july successful uptake latter half year contributed higher hiv product sales building momentum established joint venture bms september established threeway joint venture bms merck co inc merck hold european marketing authorization atripla joint venture filed marketing authorization european medicines agency october centralized licensing procedure marketing authorization application finalized approved joint venture hold one marketing authorization member states european union discussions among three companies regarding agreements manufacturing commercialization distribution atripla european union ongoing sales increases generated strong performance truvada atripla partially offset decrease sales viread due primarily patients switching vireadcontaining regimen one containing truvada andor atripla countries truvada andor atripla available despite facing continued strong competitive forces worldwide sales ambisome increased slightly one percent compared previously anticipated availability several new treatment options patients living hepatitis b infection helped hbv market expand hepsera product sales increased driven primarily sales volume growth europe addition growth product sales royalty revenue increased significantly year million royalty revenue recognized million came royalties sales tamiflu f hoffmannla roche ltd together hoffmannla roche inc roche tamiflu royalties increased due strong sales tamiflu roche including sales tamiflu related pandemic planning initiatives worldwide well elimination contractual cost goods adjustment implemented january adopted provisions statement financial accounting standards sfas revised sharebased payment sfas r began expensing fair value stockbased awards result stockbased compensation expense significant component increase operating costs expenses year ended december compared prior years discussion regarding adoption sfas r included critical accounting policies estimates judgments last years focused creating solid foundation longterm growth highlighted strong performance antiinfectives hiv hbv antifungals strategy building foundation continues opportunities acquire inlicense partner innovative table contents technologies drug candidates developing technologies alongside inhouse initiatives implemented strategy completing two significant acquisitions acquire additional innovative technologies drug candidates august completed acquisition corus pharma inc corus privatelyheld development stage biopharmaceutical company based seattle washington focused development commercialization novel drugs respiratory infectious diseases aggregate purchase price million corus one product candidate latestage clinical development aztreonam lysine inhalation treatment patients cystic fibrosis pulmonary infection pseudomonas aeruginosa november completed acquisition outstanding shares common stock myogen inc myogen publiclyheld biopharmaceutical company based westminster colorado focused discovery development commercialization small molecule therapeutics treatment cardiovascular disorders aggregate purchase price billion myogen two product candidates latestage clinical development ambrisentan treatment patients pulmonary arterial hypertension darusentan treatment patients resistant hypertension believe acquisitions corus myogen provide us opportunity expand respiratory cardiopulmonary therapeutic areas clinic made considerable progress compounds drug candidates inlicensed collaboration partners hiv first quarter dosed first patients phase clinical study novel integrase inhibitor hiv gs licensed japan tobacco inc japan tobacco february announced completion phase clinical trial announced clinical study met primary endpoint noninferiority viral load reduction hiv positive patients hepatitis area completed enrollment patients two pivotal phase clinical studies tenofovir disoproxil fumarate chronic hepatitis b second quarter collaboration partner achillion pharmaceuticals inc began dosing hcvinfected patients phase viral dynamics clinical study gs small molecule inhibitor hcv fourth quarter february based preliminary data study companies decided discontinue development gs hcv infection filed investigational new drug application fda gs nonnucleoside hcv polymerase inhibitor potential treatment hepatitis c began dosing infected patients phase clinical study gs fourth quarter anticipate data gs program second quarter although continue explore new opportunities significant unmet medical need part longterm growth strategy primary focus develop current pipeline including drug product candidates corus myogen acquisitions success commercially research development perspective product strong global organization infrastructure built past several years continue invest infrastructure facilitate continued strong growth beyond relocated european commercial medical administrative headquarters france united kingdom thereby uniting functions regulatory safety information technology groups already headquartered united kingdom undertook strategic realignment international commercial organization better build manage expand presence new existing markets year also began assessing addressing way distribute product markets serve well enhancing manufacturing capabilities growth demand products increased need timely adequate procurement clinical materials focus continuously looking ways manufacture efficiently effectively completed acquisition raylo chemicals inc raylo whollyowned subsidiary germanybased specialty chemicals company degussa ag november aggregate purchase price million located edmonton alberta canada raylos operations encompassed custom manufacturing active pharmaceutical ingredient api advanced intermediates pharmaceutical biopharmaceutical industries intend utilize edmonton site process research scaleup clinical development candidates manufacture api investigational commercial products chemical development activities improve existing commercial manufacturing processes table contents cost funding corporate development opportunities building infrastructure meeting daily operating needs continued area managements focus although generated operating cash flows billion continued explore ways accessing cash order fund corporate initiatives april took advantage favorable market corporate conditions issue billion principal amount convertible senior notes concurrently repurchased million common stock stock repurchase program purchased convertible note hedges cost million sold warrants proceeds million transactions along operating cash flows helped fund significant cash outlays required year myogen corus raylo acquisitions million payments made towards principal term loan result december cash cash equivalents marketable securities balance billion currently anticipate current cash cash equivalents marketable securities along revolving credit facility yet used adequate satisfy capital needs foreseeable future focus continue building infrastructure advancing drug candidates clinic accomplishing operational goals promoting products safety efficacy data drive higher patient adoption also intend continue building strong working relationships corporate partners roche respect tamiflu bms merck respect atripla glaxosmithkline respect hepsera due number acquisitions made significant energy invested ensure successfully integrate people processes systems edmonton seattle westminster sites also expend significant resources preparing launch ambrisentan united states well filing new drug application nda aztreonam lysine inhalation united states finally continue strengthen global infrastructure better support growing employee customer base better facilitate expanding manufacturing research development commercial activities ensure activities undertaken employees continue executed within framework high integrity critical accounting policies estimates judgments discussion analysis financial condition results operations based consolidated financial statements prepared accordance us generally accepted accounting principles preparation financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis evaluate estimates including related revenue recognition allowance doubtful accounts inventories prepaid royalties clinical trial accruals tax provision stockbased compensation base estimates historical experience various marketspecific assumptions believed reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results however may differ significantly estimates believe following critical accounting policies reflect significant judgments estimates used preparation consolidated financial statements revenue recognition product sales recognize revenues product sales persuasive evidence arrangement exists delivery customer occurred price fixed determinable collectibility reasonably assured record estimated reductions revenues government rebates medicaid reimbursements customer incentives cash discounts prompt payment distributor fees expected returns expired products estimates deducted gross product sales time revenues recognized reductions gross product sales government rebates significantly impact reported net product sales based upon certain estimates require complex significant management judgments table contents government rebates estimate amounts payable us governmentmanaged medicaid programs well certain qualifying federal state government programs reimbursement portions retail price prescriptions filled covered programs government rebates invoiced directly us recorded accrued liabilities consolidated balance sheets qualified programs purchase products wholesalers lower contractual government price wholesalers charge back us difference acquisition cost lower price record allowances accounts receivable estimate sales allowances based contractual terms historical utilization rates new information regarding changes programs regulations guidelines would impact amount actual rebates expectations regarding future utilization rates programs channel inventory data obtained major us wholesalers accordance inventory management agreements million million million respectively representing total gross product sales respectively deducted gross product sales government rebates based current information available us actual government rebates claimed periods varied less estimates recorded periods december accrued government rebates million million respectively accrued liabilities allowance million million respectively recorded accounts receivable following table summarizes aggregate activity accrued government rebates allowance accrued liabilities accounts balance deducted balance beginning charged end year expense accruals year year ended december government rebates allowances accrued liabilities activity related sales activity related sales prior total year ended december government rebates allowances accrued liabilities activity related sales activity related sales prior total contract revenue contract revenue research development rd recorded performance occurs earnings process completed based performance requirements contract nonrefundable contract fees performance obligations exist continuing involvement us recognized payments received collection reasonably assured revenue nonrefundable upfront license fees milestone payments continue involvement development collaboration obligation supply product recognized performance occurs obligations completed accordance specific terms obligations types arrangements revenues recognized obligation fulfilled ratably development manufacturing period revenues associated substantive atrisk milestones recognized based upon achievement milestones defined respective agreements advance payments received excess amounts earned classified deferred revenue table contents allowance doubtful accounts also maintain allowance doubtful accounts estimated losses resulting inability customers make required payments allowance based analysis several factors including limited contractual payment terms historical payment patterns customers individual customer circumstances analysis days sales outstanding customer geographic region review local economic environment potential impact government funding reimbursement practices financial condition customers economic environment operate deteriorate resulting inability make payments additional allowances may required allowance doubtful accounts balance percentage total accounts receivable materially change december december believe allowance doubtful accounts adequate cover anticipated losses current conditions however significant deterioration factors especially respect government funding reimbursement practices european market could materially change expectations result increase allowance doubtful accounts inventories record writedowns value inventory based review bad batches experienced manufacturing process well quality control reviews inventory generally record inventory writedowns relating estimated obsolescence risk competition primarily shelf life products long however current assumptions future production inventory levels demand competition change actual market conditions less favorable projected management additional inventory writedowns may required could negatively impact product gross margins results operations prepaid royalties capitalize royalties prepaid cost specifically related emtricitabine royalties paid emory university emory hiv indication based present value future royalty obligation would expect pay emory assuming certain expected future levels product sales incorporating emtricitabine technology present value future royalty obligation derived using weighted average cost capital review quarterly expected future sales levels products indicators might require writedown net recoverable value asset change estimated life prepaid royalty potential indicators impairment include launch significant product competitor significant deviations recognized product sales compared forecast product safety issues recalls amortize prepaid royalties based effective royalty rate derive forecasted hiv product sales incorporating emtricitabine product sales forecasts prepared annually determined using best estimates future activity considering factors historical expected future patient usage uptake products introduction complimentary combination therapies products future product launch plans previously unanticipated significant change occurs sales forecasts including introduction competing product us one competitors hiv market emtricitabine would prospectively update royalty rate used amortize prepaid royalties may increase future royalty expense december prepaid royalty asset relating emtricitabine royalties paid emory million amortization expense relating prepaid royalty asset million million years ended december respectively clinical trial accruals record accruals estimated clinical study costs clinical studies performed thirdparty contract research organizations cros costs significant component rd expenses incurred cro costs million million million respectively table contents accrue costs clinical studies performed cros straightline basis service periods specified contracts adjust estimates required based upon ongoing review level effort costs actually incurred cro validate accruals quarterly vendors perform detailed reviews activities related significant contracts based upon results validation processes assess appropriateness accruals make adjustments deem necessary ensure expenses reflect actual effort incurred cros generally significant portion total clinical trial costs associated start activities trial patient enrollment extensively outsource clinical trial activities usually perform small portion startup activities house result cros typically perform total startup activities trials including document preparation site identification screening preparation prestudy visits training program management budgeted basis costs typically total contract value actual basis percentage range significantly wider many contracts either expanded reduced scope compared original budget startup costs particular trial change significantly startup costs usually occur within months contract executed milestone event driven nature remaining activities related costs patient monitoring administration generally occur ratably throughout life individual contract study contracts negotiated fixed unit prices vary length six months single dose phase study two years complex phase study average length contracts upper end range order provide longterm safety efficacy data support commercial launches truvada viread atripla emtriva hepsera material cro contracts terminable us upon written notice gilead generally liable actual effort expended cro point time contract regardless payment status amounts paid advance services performed refunded contract terminated december differences actual estimated activity levels particular study significant enough require material adjustment however management receive complete accurate information vendors underestimated activity levels associated study given point time would record additional potentially significant rd expenses future periods tax provision estimate income tax provision including deferred tax assets liabilities based significant management judgment evaluate realization portion deferred tax assets quarterly basis record valuation allowance reduce deferred tax assets amounts likely realized consider future taxable income ongoing tax planning strategies historical financial performance assessing need valuation allowance part purchase myogen fourth quarter determined likely certain acquired deferred tax assets related state net operating loss carryforwards would realized therefore established valuation allowance approximately million expect realize deferred tax assets previously recorded valuation allowance would reduce valuation allowance period determination first made adjustment made fourth quarter determined likely certain deferred tax assets would realized therefore released related valuation allowance resulted income tax benefit approximately million future effective income tax rate may affected factors changes tax laws regulations rates changing interpretation existing laws regulations impact accounting stockbased compensation changes international organization changes overall levels income tax table contents income tax returns routinely audited various state foreign tax authorities differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions periodically evaluate exposures associated tax filing positions believe positions comply applicable laws record liabilities based upon sfas accounting contingencies believe items currently pending material adverse effect consolidated financial statements included annual report although adverse resolution one items quarterly reporting period covered consolidated financial statements could material impact results operations period stockbased compensation december financial accounting standards board fasb issued sfas r requires sharebased payments employees directors including grants stock options recognized statement operations based fair values sfas r supersedes accounting principles board opinion accounting stock issued employees apb amends sfas statement cash flows january adopted sfas r using modified prospective method adoption permitted sfas r requires compensation expense recorded nonvested stock options stockbased awards beginning first quarter adoption accordance modified prospective method prior period amounts restated reflect provisions sfas r prior adoption sfas r accordance provisions sfas elected follow apb fasb interpretation accounting certain transactions involving stock compensationan interpretation apb opinion accounting employee stockbased plans apb exercise price employee director stock options equal greater fair value underlying stock date grant compensation expense recognized however required sfas pro forma impact expensing fair value stock options employee stock purchase plan disclosed notes consolidated financial statements connection adoption sfas r refined valuation assumptions methodologies used derive assumptions however elected continue using blackscholes option valuation model fair value stock options granted prior adoption sfas r calculated using multiple option approach fair value stock options granted beginning january calculated using single option approach concurrent adoption sfas r determined blend historical volatility along implied volatility traded options stock would better measure market conditions expected volatility previously used historical stock price volatility reliable source volatility data estimate weightedaverage expected life stock options based historical cancellation exercise data related stock options well contractual term vesting terms awards record stockbased compensation expense using graded vesting expense attribution approach nonvested stock options granted prior adoption sfas r consistent expense attribution approach used historical sfas disclosures using straight line expense attribution approach stock options granted adoption sfas r currently believe straightline expense attribution approach better reflects level service provided vesting period awards stockbased compensation expense related stock options recognized net estimated forfeitures estimated forfeitures based historical experience result adoption sfas r recognize benefit stockbased compensation additional paidincapital apic incremental tax benefit realized tax attributes currently available us utilized addition elected account indirect benefits stockbased compensation research tax credit extraterritorial income deduction consolidated statement operations rather apic table contents year ended december recognized stockbased compensation expense million operating expenses capitalized million inventory december unrecognized stockbased compensation million related nonvested stock options expect expense estimated weightedaverage period two years senior management discussed development selection disclosure critical accounting policies audit committee board directors audit committee reviewed disclosure presented relating results operations total revenues total revenues billion billion billion included total revenues product sales royalty revenue contract revenue product sales product sales last three years consisted following thousands change change hiv products truvada viread atripla emtriva total hiv products sales hepsera ambisome total product sales total product sales increased compared compared case primarily due increase volume sales hiv products significant percentage product sales continue denominated foreign currencies use forward contracts hedge percentage forecasted international sales primarily denominated euro reduces eliminate fluctuations sales due changes foreign currency exchange rates hiv products viread emtriva truvada atripla approved sale united states october july august july respectively viread emtriva truvada approved sale european union february october february respectively currently seeking approval atripla sale european union hiv product sales increased compared compared primarily driven product volume growth experienced steady prescription gains hiv product portfolio throughout average selling prices hiv products increased compared primarily driven higher overall selling prices hiv products well transition patients united states coverage medicaid medicare part reduced amount medicaid claims result table contents transition estimated assuming patients dually eligible medicaid fact transition medicare part benefit net product sales resulting reduction medicaid claims approximately million truvada truvada sales increased compared primarily driven strong sales volume growth across major geographic regions truvada sales accounted total hiv product sales respectively reflecting strong position nrti backbone choice united states well rapid significant uptake key european territories truvada sales increased united states first full year truvada sales primarily due patients new therapy secondarily patients switching regimens including containing viread andor emtriva viread viread sales decreased compared primarily due patients switching vireadcontaining regimen one containing truvada countries truvada available partially offset sales volume increases latin america viread sales relatively consistent sales levels resulting continued strong performance viread despite offsetting impact patients switching vireadcontaining regimen one containing truvada countries truvada available atripla atripla sales million since consolidate atripla product sales primary beneficiary joint venture bms sales included approximately million relating sustiva atripla approved sale united states july accounted hiv product sales since launch december emtriva emtriva sales decreased compared compared decreases years primarily driven impact patients switching emtrivacontaining regimen one containing truvada andor atripla countries products available hepsera hepsera sales increased compared compared primarily driven sales volume growth europe united states hepsera sales volume also increased respect sales hepsera glaxosmithkline inc gsk sell hepsera gsk manufacturing cost connection gsks distribution activities asia royalties earned us sales hepsera gsk recorded royalty revenue ambisome sales ambisome increased one percent compared increased four percent compared increases comparative periods primarily due increased sales united states ambisome product sales united states relate solely sales ambisome astellas pharma inc astellas recorded manufacturing cost royalties earn sales ambisome astellas discussed royalty revenue comparative periods although ambisome sales volume increased european union lower pricing regions slightly reduced related net product sales recognized expect total product sales marketed products continue grow continue expand sales marketing efforts table contents royalty revenue following table summarizes period period changes royalty revenue thousands change change royalty revenue significant sources royalty revenue sales tamiflu roche sales ambisome united states astellas royalty revenue million increase compared primarily driven recognition tamiflu royalties roche million increase tamiflu royalties due higher tamiflu sales recorded roche including sales related pandemic planning initiatives worldwide well elimination contractual cost goods adjustment resulting dispute resolution november historically reduced amount tamiflu royalties recognized us recognize royalties tamiflu sales roche quarter following quarter sold royalty revenue million increase compared primarily driven amounts received connection dispute resolution discussed recognition higher royalties received roche higher tamiflu sales caused significant flu season particularly japan well fulfillment orders pandemic readiness supplies certain countries november resolved dispute roche relating development license agreement agreed terminate related arbitration pending roche us related dispute resolution roche also paid us million recognized royalty revenue consisted million relating disputed royalties million relating reimbursement contractual cost goods adjustment previously reduced earned royalties million relating updating royalties payable us first nine months based thencurrent royalty rates instead prior years effective royalty rate royalty revenue earned us roche including amounts recognized dispute resolution million million respectively royalty revenue earned sales ambisome astellas million seven percent decrease million contract revenue following table summarizes period period changes contract revenue thousands change change contract revenue contract revenue million decrease compared contract revenue consisted primarily net product distribution service revenue sales flolan million milestone payment received osi pharmaceuticals inc osi related first commercial sale macugen european union revenue earned various contract manufacturing projects well amortization previously deferred milestone revenues contract revenue consisted primarily million milestone payment earned osi related first commercial sale macugen united states revenue earned various contract manufacturing projects well amortization previously deferred milestone revenues table contents cost goods sold product gross margin following table summarizes period period changes product sales thousands cost goods sold thousands product gross margin change change total product sales cost goods sold product gross margin product gross margin compared lower gross margin primarily due launch atripla united states million writedowns inventory gilead access program estimated net realizable value well product mix changes patients continue switch viread higher margin product truvada andor atripla partially offset lower effective royalty rate resulting july emtricitabine royalty buyout discussed lower api costs higher average selling prices hiv products united states atripla product sales decreased product gross margin without corresponding impact product gross profit primary beneficiary joint venture bms consolidate atripla product sales benefit product gross margin truvada portion atripla sustiva portion atripla product sales carries zero product gross profit since joint venture purchases sustiva api bms bmss estimated net selling price sustiva us market product gross margin compared primarily due product mix changes patients switched viread higher margin product truvada prior july paid royalties emory worldwide net sales product containing emtrcitabine july royalty pharma purchased respectively royalty interest owned emory exchange elimination royalty obligation result purchase capitalized million prepaid royalties representing share million purchase price third quarter began amortize prepaid royalty cost goods sold remaining life underlying patent based effective royalty rate derived forecasted sales products containing emtricitabine recorded royalties royalty pharma based actual emtricitabine net sales relative royalty pharmas ownership interest underlying emory royalty interest expect product gross margin lower driven higher mix atripla product sales include sustiva portion zero product gross profit partially offset gross margin improvements driven lower api costs continued benefit associated prepaid emtricitabine royalties research development expenses following table summarizes period period changes major components rd expenses last three years thousands change change research clinical development pharmaceutical development total research development rd expenses consist primarily personnel costs including salaries benefits stockbased compensation clinical studies performed cros materials supplies licenses fees overhead allocations consisting various support facilities related costs rd activities separated three main categories research clinical development pharmaceutical development research costs typically consist preclinical toxicology costs clinical development costs include costs phase clinical trials pharmaceutical development expenses consist costs product formulation chemical analysis table contents rd expenses increased million compared primarily due increased compensation benefits million due largely higher headcount included stockbased compensation expense million adoption sfas r january well increased contract service clinical study expenses million relating clinical product development research activities hiv hepatitis programs newlyacquired programs respiratory cardiopulmonary areas higher expenses partially offset lower milestone payments made japan tobacco compared related licensing development lead integrase inhibitor candidate gs well million payment emory connection amendment license agreement emory related obligation develop emtricitabine hepatitis b indication general significant collaboration payments seen payments japan tobacco emory period cause rd expenses fluctuate period period rd expenses increased million compared primarily due million payment made emory mentioned million payment made japan tobacco related execution hiv integrase license agreement gs increased compensation benefits million higher headcount increased clinical product development activities associated hiv hepatitis programs payments made emory japan tobacco expensed underlying technologies incomplete alternative future use case emory significant rd activities expected next several years expect rd expenses increase levels reflecting increased spending internal collaborative rd efforts well product licensing activity relating expectation product candidates progress advanced clinical trials especially respiratory cardiopulmonary areas selling general administrative expenses following table summarizes period period changes selling general administrative sga expenses last three years thousands change change selling general administrative sga expenses increased million compared higher expenses primarily driven higher headcount increased compensation benefits million including stockbased compensation expense million adoption sfas r january increased expenses million contract services promotional programs relating business growth business development activities activities prepare us launch atripla million writeoff certain capital assets related renovations corporate headquarter campus addition beginning began reporting net foreign exchange transaction gains losses well fair value changes derivative instruments designated hedges interest income net amounts previously reported sga expenses reclassified enhance comparability financial statements companies prior year amounts although insignificant reclassified consistent current year presentation sga expenses increased million compared increase primarily due increase compensation benefits million due largely higher headcount increase market research speakers programs symposia costs million million severance relocation expenses associated relocation european commercial medical administrative headquarters france united kingdom increase medical education costs million increase journal advertising costs million well costs related general expansion sales marketing activities worldwide increases partially offset decrease bad debt expense million result higher collections activity certain european countries table contents expect sga expenses increase primarily due higher costs incurred administrative activities sales marketing efforts support business growth well sales force expansion planned anticipated ambrisentan launch united states higher costs related ongoing investment global commercial organization additional hiring promotional programs well incremental operating expenses associated acquisitions corus myogen purchased inprocess research development connection acquisitions myogen corus recorded purchased inprocess research development iprd expense billion million respectively year ended december purchased iprd expense myogen represented estimated fair value myogens incomplete research development programs yet reached technological feasibility alternative future use acquisition date therefore expensed upon acquisition summary research development programs acquisition date follows estimated acquisition date fair value program description status development millions ambrisentan orally active nonsulfonamide propanoic acidclass endothelin phase clinical trials completed prior acquisition date filed nda receptor antagonist era treatment pulmonary arterial fda december february fda granted us priority review hypertension status nda marketing approval ambrisentan established target review date june darusentan orally active etaselective era treatment resistant phase clinical development acquisition date date filing hypertension estimated fair value purchased iprd determined using income approach discounts expected future cash flows present value estimated related future net cash flows using present value riskadjusted discount rate significant assumption based estimated internal rate return myogens operations comparable estimated weighted average cost capital companies myogens profile projected cash flows ambrisentan darusentan programs based key assumptions estimates revenues operating profits related programs considering stages development time resources needed complete development approval related products life potential commercialized products associated risks including inherent difficulties uncertainties developing drug compound obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets purpose estimating fair value ambrisentan program estimated program approximately complete acquisition date based estimated time cost complete phase clinical trials completed based assumption would incur future research development costs approximately million million date acquisition including year commercialization expected occur material net cash inflows estimated begin ambrisentan assuming necessary regulatory approvals would received product would successfully commercialized date table contents purpose estimating fair value darusentan program estimated program approximately complete acquisition date based estimated time cost complete remaining efforts would include completion phase clinical development well preparing filing nda fda based assumption would incur future research development costs approximately million million date acquisition including year commercialization expected occur material net cash inflows estimated begin darusentan assuming necessary regulatory approvals would received product would successfully commercialized date remaining efforts completing myogens iprd programs primarily consist clinical trials cost length success extremely difficult predict obtaining necessary regulatory approvals numerous risks uncertainties exist could prevent completion development including ability enroll patients clinical trials possibility unfavorable results clinical trials risk failing obtain fda regulatory body approvals feedback regulatory authorities results clinical trials might require modifications delays later stage clinical trials additional trials performed certain either ambrisentan darusentan purchased myogen approved united states countries outside united states whether marketing approvals significant limitations use future discussions regulatory agencies determine amount data needed timelines review may differ materially current projections acquired product candidates development may never successfully commercialized result may make strategic decision discontinue development product candidates example believe commercialization difficult relative opportunities pipeline programs completed timely basis prospects future revenue growth may adversely impacted assurance given underlying assumptions used forecast cash flows timely successful completion projects materialize estimated reasons among others actual results may vary significantly estimated results purchased iprd expense corus represented estimated fair value coruss incomplete inhaled aztreonam lysine cystic fibrosis research development program yet reached technological feasibility alternative future use acquisition date therefore expensed upon acquisition description program acquisition date follows estimated acquisition date fair value program description status development millions inhaled aztreonam lysine cystic fibrosis aztreonam formulation inhalation used gramnegative phase clinical trials acquisition date date filing bacteria cause lung infections patients cystic fibrosis estimated fair value purchased iprd determined using income approach discounts expected future cash flows present value estimated related future net cash flows using present value riskadjusted discount rate significant assumption based estimated internal rate return coruss operations comparable estimated weightedaverage cost capital companies coruss profile projected cash flows aztreonam lysine inhalation program based key assumptions estimates revenues operating profits related program considering stage development time resources needed complete development approval related product life potential commercialized product associated risks including inherent difficulties uncertainties developing drug compound obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets coruss two earlystage candidates included valuation purchased iprd earlystage programs identifiable revenues expenses associated table contents purpose estimating fair value aztreonam program estimated program approximately complete acquisition date based estimated time cost complete remaining efforts would include completion phase clinical development well preparing filing nda fda based assumption would incur future research development costs approximately million million date acquisition including year commercialization expected occur material net cash inflows estimated begin aztreonam program assuming necessary regulatory approvals would received product would successfully commercialized date remaining efforts completing coruss iprd program primarily consist clinical trials cost length success extremely difficult predict obtaining necessary regulatory approvals numerous risks uncertainties exist could prevent completion development including ability enroll patients clinical trials possibility unfavorable results clinical trials risk failing obtain fda regulatory body approvals feedback regulatory authorities results clinical trials might require modifications delays later stage clinical trials additional trials performed certain aztreonam lysine cystic fibrosis purchased corus approved united states countries outside united states whether marketing approvals significant limitations use future discussions regulatory agencies determine amount data needed timelines review may differ materially current projections acquired product candidate development may never successfully commercialized result may make strategic decision discontinue development product candidate example believe commercialization difficult relative opportunities pipeline program completed timely basis prospects future revenue growth may adversely impacted assurance given underlying assumptions used forecast cash flows timely successful completion project materialize estimated reasons among others actual results may vary significantly estimated results gain warrant pursuant march agreement eyetech pharmaceuticals inc eyetech predecessor osi received warrant purchase shares eyetech series b convertible preferred stock exercisable price per share january eyetech completed initial public offering common stock time adjusted fair value warrant resulting gain million time fair value warrant estimated using blackscholes valuation model volatility rate discount rate end first quarter exercised warrant net basis using shares eyetech common stock consideration exercise price subsequently held shares eyetech common stock second quarter sold eyetech shares owned realized gain approximately million included interest income net makewhole payment convertible debt redemption october called redemption outstanding convertible senior notes due december convertible senior notes redeemed november provisional redemption based upon market price common stock exceeding certain thresholds aggregate principal amount outstanding notes million convertible senior notes redeemable redemption price equal principal amount notes plus cash payment equal accrued unpaid interest redemption date cash makewhole payment equal per principal value notes less interest actually paid accrued unpaid date issuance notes redemption date interest convertible senior notes ceased accrue redemption date remaining right holders thereafter receive redemption payment including accrued unpaid interest redemption date makewhole payment alternatively note holders could elect convert notes shares common stock price per share shares common stock per principal amount notes holders substantially outstanding notes converted table contents notes shares common stock prior november redemption date result conversions shares common stock issued note holders connection redemption made aggregate makewhole payments million note holders classified within consolidated statement operations interest income net recorded interest income net million million million respectively amounts included reclassification net foreign exchange transaction gains losses discussed increases primarily attributable higher average cash investment balances prior years interest income depend principally upon prevailing interest rates level cash cash equivalent marketable securities balances interest expense incurred interest expense million compared million million april issued million principal amount convertible senior notes due notes million principal amount convertible senior notes due notes collectively notes private placement pursuant rule securities act amended notes notes issued par bear interest rates respectively debt issuance costs million connection issuance notes recorded noncurrent assets amortized interest expense straightline basis contractual terms notes increase interest expense primarily due interest term loan entered december interest notes decrease interest expense primarily attributable conversion million convertible senior notes shares common stock november expect interest expense decrease continue make payments towards term loan minority interest joint venture minority interest joint venture consolidated financial statements reflects bmss interest operating results joint venture bms united states primary beneficiary joint venture determined financial accounting standards board fasb interpretation consolidation variable interest entities consolidate operations joint venture consolidated financial statements operations joint venture commenced activities primarily focusing coformulation oncedaily single tablet regimen achieving bioequivalence various coformulations achieved bioequivalence formulation single tablet regimen end nda filed april single tablet regimen july received approval fda single tablet regimen united states given trade name atripla provision income taxes provision income taxes million million million respectively included operating income pretax charges million billion purchased iprd expenses associated corus myogen acquisitions respectively effective tax rate differs us federal statutory rate primarily due federal tax nondeductible purchased iprd expenses state taxes offset tax credits certain operating earnings nonus subsidiaries considered indefinitely invested outside united states effective tax rate differs us federal statutory rate due generally state taxes offset recognition previously unbenefitted net operating loss tax credit carryforwards certain operating earnings nonus subsidiaries considered indefinitely invested outside united states onetime benefit qualifying dividends american jobs creation act ajca table contents october ajca signed law ajca allows deduction certain qualified foreign earnings repatriated defined ajca elected apply provision qualifying earnings repatriated earnings repatriation resulted onetime tax provision benefit approximately million recognized effective income tax rate differs us federal statutory rate due generally recognition previously unbenefitted net operating losses tax credit carryforwards certain earnings operations jurisdictions lower tax rates united states jurisdictions us taxes provided earnings planned reinvested indefinitely outside united states partially offset state taxes june fasb issued fasb interpretation accounting uncertainty income taxes fin interpretation sfas accounting income taxes sfas fin clarifies accounting uncertainty income taxes recognized enterprises financial statements accordance sfas prescribing minimum recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return fin also provides guidance derecognition classification interest penalties accounting interim periods disclosure transition fin effective fiscal years beginning december adopted fin january required preliminary determination impact adopting standard range million million actual amount recorded charge accumulated deficit consolidated balance sheet upon adoption fin liquidity capital resources following table summarizes cash cash equivalents marketable securities working capital cash flow activity end last three years thousands december cash cash equivalents marketable securities working capital year ended december cash provided used operating activities investing activities financing activities cash cash equivalents marketable securities cash cash equivalents marketable securities totaled billion december decrease december decrease million primarily due net cash paid billion acquisitions myogen raylo corus cash million paid toward principal outstanding term loan decreases partially offset net cash provided operations billion net proceeds million issuance notes related transactions proceeds issuance stock employee stock plans million table contents cash cash equivalents marketable securities totaled billion december increase december increase billion primarily due net cash provided operations million proceeds million term loan entered proceeds issuance stock employee stock plans million increases partially offset capital expenditures million working capital working capital december billion compared billion december significant factors resulted decrease working capital billion decrease cash cash equivalents shortterm marketable securities primarily due need fund significant acquisition activities well decrease marketable securities portfolio decrease resulting classification certain marketable securities longterm securities million increase accounts payable primarily due launch atripla july related purchases sustiva api bms bmss approximate market value sustiva order joint venture build inventory levels supply increasing atripla demand working capital decreases partially offset million increase inventories primarily due increase atripla inventory included sustiva api bmss approximate market value sustiva million increase accounts receivable primarily due increased sales lower receivables collections certain european countries collections traditionally slower working capital december billion compared billion december significant factors resulted increase working capital billion increase cash cash equivalents marketable securities million increase inventories meet growing demand hiv products hepsera well meet gilead access program requirements million increase prepaids current assets primarily related current portion prepaid royalties emory emtricitabine million increase deferred tax assets million increase accounts receivable primarily due increased sales partially offset higher collection activity especially certain european countries collections traditionally slower increases partially offset million increase income taxes payable primarily due higher profitability partially offset tax benefits employee stock plans million increase reflecting current portion million term loan entered december million increase accrued liabilities including increases accruals related medicaid rebates royalty expenses sales marketing expenses partially offset decrease liability associated fair value forward currency contracts us dollar strengthened euro table contents cash provided operating activities cash provided operating activities billion comprised primarily billion net loss adjusted noncash items billion purchased iprd expense stockbased compensation expense million million tax benefits related employee stock plans partially offset million excess tax benefits stock option exercises million net cash outflow related changes operating assets liabilities including million increased inventories partially offset million increased accounts payable related primarily increases atripla inventory mentioned million increased accounts receivable due product sales growth lower receivables collections certain european countries collections traditionally slower cash provided operating activities million comprised primarily million net income adjusted noncash items million tax benefits employee stock plans million net cash outflow related changes operating assets liabilities included million prepaid royalties made emory related emtricitabine cash provided operating activities million comprised primarily million net income adjusted noncash items million deferred income taxes primarily resulting utilization net operating losses tax credit carryforwards offset taxable income partially offset million net cash outflow related changes operating assets liabilities included million increase accounts receivable primarily resulting product sales growth cash used investing activities cash used investing activities primarily related purchases sales maturities availableforsale securities acquisitions myogen raylo corus well capital expenditures cash used investing activities primarily related purchases sales maturities availableforsale securities used billion cash investing activities compared million million increase cash used investing activities primarily result acquisitions myogen raylo corus total billion net cash billion provided sales maturities purchases availableforsale securities compared net cash used million million used net cash investing activities including capital expenditures million million invested nonmarketable securities issued certain strategic partners capital expenditures made related primarily expanding certain aspects manufacturing capabilities upgrading facilities well additional spending computer laboratory equipment accommodate continued growth capital expenditures also included purchase two buildings previously leased foster city california headquarters table contents cash provided financing activities april issued million principal amount convertible senior notes due million principal amount convertible senior notes due collectively notes private placement pursuant rule securities act amended part net proceeds notes issuances billion deducting initial purchasers discount estimated offering expenses used repurchase million common stock concurrent issuance notes purchased convertible note hedges private transactions cost million also sold warrants acquire million shares common stock private transactions received net proceeds million taken together convertible note hedges warrants intended reduce potential dilution upon future conversions notes effectively increasing initial conversion price notes total transactions generated net proceeds million us cash provided financing activities million primarily resulting million net proceeds generated issuance notes related transactions mentioned addition received proceeds employee stock option exercises million well million excess tax benefits stock option exercises cash inflows partially offset million paid towards principal term loan cash provided financing activities primarily related proceeds million term loan million stock option exercises stock purchases made employee stock plans cash provided financing activities primarily related million proceeds stock option exercises stock purchases employee stock purchase plan information december uncollateralized revolving credit facility million outstanding amounts capacity revolving credit facility continue increase maximum million commensurate repayments principal term loan believe existing capital resources supplemented cash generated operations adequate satisfy capital needs foreseeable future future capital requirements depend many factors including limited following commercial performance current future products progress scope rd efforts including preclinical studies clinical trials cost timing outcome regulatory reviews expansion sales marketing capabilities administrative expenses possibility acquiring manufacturing capabilities additional office facilities possibility acquiring companies new products establishment additional collaborative relationships companies defense costs associated settlements adverse results litigation government investigations may future require additional funding could form proceeds equity debt financings funding required assure available us favorable terms offbalance sheet arrangements offbalance sheet arrangements currently material reasonably likely material financial position results operations table contents contractual obligations contractual obligations consist debt obligations capital operating leases well purchase obligations primarily form capital commitments purchase obligations active pharmaceutical ingredients inventoryrelated items clinical trials contracts following table summarizes significant enforceable legally binding obligations future commitments obligations related contracts likely continue regardless fact cancelable december thousands payments due period less one contractual obligations total year years years years convertible senior notes term loan capital lease obligations operating lease obligations capital commitments purchase obligations clinical trials total december outstanding principal billion notes issued april december outstanding principal million million fiveyear term loan entered december december firm capital project commitments approximately million primarily relating expansion certain aspects manufacturing capabilities upgrading facilities december firm commitments purchase active pharmaceutical ingredients inventoryrelated items amounts disclosed represent minimum purchase requirements actual purchases expected significantly exceed amounts december several clinical studies various clinical trial phases significant clinical trial expenditures cros although contracts cros cancelable generally cancelled contracts amounts reflect commitments based existing contracts reflect future modifications existing contracts anticipated potential new contracts excludes interest related payments convertible senior notes term loan capital lease obligations addition committed make potential future milestone payments thirdparties part licensing development programs payments agreements generally become due payable upon achievement certain developmental regulatory andor commercial milestones achievement milestones neither probable reasonably estimable contingencies recorded consolidated balance sheet included table recent accounting pronouncements june fasb issued fasb interpretation accounting uncertainty income taxes fin interpretation sfas accounting income taxes sfas fin clarifies accounting uncertainty income taxes recognized enterprises financial statements accordance sfas prescribing minimum recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return fin also provides guidance derecognition classification interest penalties accounting interim periods disclosure transition fin effective fiscal years beginning december adopted fin january required preliminary determination impact adopting standard range million million actual amount recorded charge accumulated deficit consolidated balance sheet upon adoption fin table contents item quantitative qualitative disclosures market risk foreign currency exchange risk operations include manufacturing sales activities united states canada ireland well sales activities countries outside united states including europe australia result financial results could significantly affected factors changes foreign currency exchange rates weak economic conditions foreign markets distribute products operating results exposed changes exchange rates us dollar various foreign currencies significant euro british pound australian dollar us dollar strengthens currencies relative value sales made respective foreign currency decreases conversely us dollar weakens relative amounts sales increase overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar relative foreign currencies transact significant amounts business enter foreign exchange forward contracts mitigate impact changes currency exchange rates cash flows sales denominated foreign currency well foreign currencydenominated net monetary assets liabilities significant percentage product sales denominated foreign currencies increases value us dollar foreign currencies past reduced may future reduce us dollar return sales negatively impact financial condition use forward contracts hedge percentage forecasted international sales primarily denominated euro currency recent years foreign currency exchange fluctuations positively negatively impacted product sales gross margin however full impact foreign currency fluctuations moderated hedge program following table summarizes notional amounts average currency exchange rates fair values open foreign exchange forward contracts december contracts maturities one year less average rates stated terms amount foreign currency per us dollar fair values represent estimated settlement amounts december notional amounts fair values us dollars thousands currency notional amount average rate fair value british pound euro australian dollar total total notional amount billion total fair value liability million open foreign exchange forward contracts december compares total notional amount million total fair value relating asset million open foreign exchange forward contracts december interest rate risk portfolio availableforsale marketable securities fixed variablerate liabilities create exposure interest rate risk respect investment portfolio adhere investment policy requires us limit amounts invested securities based duration industry group investment type issuer except securities issued us government goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return table contents following table summarizes expected maturities average interest rates interestgenerating assets interestbearing liabilities december dollars thousands years ending december total fair value december thereafter assets availableforsale debt securities average interest rate liabilities convertible senior notes average interest rate term loan including current portion average interest rate capital lease obligations including current portion average interest rate april issued million principal amount convertible senior notes due notes million principal amount convertible senior notes due notes private placement pursuant rule securities act amended notes notes issued par bear interest rates respectively may converted subject certain circumstances december entered million fiveyear term loan average interest rates based implied threemonth libor forward rates yield curve december option choose borrowing maturity based one two three sixmonth libor terms loan minimum principal amount repaid end calendar quarter beginning march five percent outstanding amount interest accrued rate libor plus tiered contractual rate basis points prepay term loan time whole part together accrued interest prepaid principal without penalty premium year ended december million term loan principal repaid outstanding interest principal december payable demand international credit risk accounts receivable balance december million compared million december growth accounts receivable balances primarily due higher product sales hiv products united states europe certain countries payments typically slow primarily greece italy portugal spain aggregated accounts receivable balance significant cases slow payment practices reflect pace governmental entities reimburse customers turn may increase credit risk related certain customers sales customers countries tend relatively slowpaying past increased future may increase average length time accounts receivable outstanding december past due accounts receivable greece italy portugal spain totaled million million days past due based contractual terms receivables date experienced significant losses respect collection accounts receivable believe substantially accounts receivable balances collectible perform credit evaluations customers financial condition generally required collateral table contents item financial statements supplementary data financial statements required item set forth beginning report incorporated herein reference item changes disagreements accountants accounting financial disclosure applicable item controls procedures evaluation disclosure controls procedures evaluation december carried supervision participation management including chief executive officer chief financial officer effectiveness design operation disclosure controls procedures defined sec rules controls procedures company designed ensure information required disclosed company reports files securities exchange act amended exchange act recorded processed summarized reported within required time periods based upon evaluation chief executive officer chief financial officer concluded disclosure controls procedures effective b managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined exchange act rule af internal control system designed provide reasonable assurance regarding preparation fair presentation financial statements external purposes accordance generally accepted accounting principles internal control systems matter well designed inherent limitations provide reasonable assurance objectives internal control system met supervision participation management including chief executive officer chief financial officer conducted evaluation effectiveness internal control financial reporting based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission coso based evaluation concluded internal control financial reporting effective december independent registered public accounting firm ernst young llp audited consolidated financial statements included annual report issued report managements assessment internal control financial reporting well effectiveness internal control financial reporting december report audit internal control financial reporting appears table contents report independent registered public accounting firm board directors stockholders gilead sciences inc audited managements assessment included accompanying managements report internal control financial reporting gilead sciences inc maintained effective internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission coso criteria gilead sciences incs management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting responsibility express opinion managements assessment opinion effectiveness companys internal control financial reporting based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting evaluating managements assessment testing evaluating design operating effectiveness internal control performing procedures considered necessary circumstances believe audit provides reasonable basis opinion companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion managements assessment gilead sciences inc maintained effective internal control financial reporting december fairly stated material respects based coso criteria also opinion gilead sciences inc maintained material respects effective internal control financial reporting december based coso criteria also audited accordance standards public company accounting oversight board united states consolidated balance sheets gilead sciences inc december related consolidated statements operations stockholders equity cash flows three years period ended december related financial statement schedule report dated february expressed unqualified opinion thereon ernst young llp palo alto california february table contents c changes internal control financial reporting management including chief executive officer chief financial officer evaluated changes internal control financial reporting occurred quarter ended december concluded change quarter materially affected reasonably likely materially affect internal control financial reporting item b information applicable part iii item directors executive officers corporate governance information required item concerning directors executive officers incorporated reference sections definitive proxy statement filed sec pursuant regulation connection annual meeting stockholders proxy statement headings nominees board committees meetings executive officers section beneficial ownership reporting compliance written code ethics applies directors employees including executive officers including without limitation principal executive officer principal financial officer principal accounting officer controller persons performing similar functions code ethics available website httpwwwinvestorsgileadcom corporate governance changes waivers code ethics disclosed website intend satisfy disclosure requirement item form k regarding amendment waiver provision code ethics disclosing information website item executive compensation information required item incorporated reference sections proxy statement headings executive compensation compensation committee interlocks insider participation compensation committee report compensation nonemployee directors item security ownership certain beneficial owners management related stockholder matters information required item incorporated reference section proxy statement headings security ownership certain beneficial owners management securities authorized issuance equity compensation plans item certain relationships related transactions director independence information required item incorporated reference section proxy statement headings nominees certain relationships related transactions item principal accountant fees services information required item incorporated reference section proxy statement heading principal accountant fees services table contents part iv item exhibits financial statement schedules following documents filed part annual report index list consolidated financial statements report independent registered public accounting firm audited consolidated financial statements consolidated balance sheets consolidated statements operations consolidated statement stockholders equity consolidated statements cash flows notes consolidated financial statements schedule ii included report schedules omitted required required information included financial statements notes thereto exhibits following exhibits filed herewith incorporated reference exhibit exhibit footnote number description document asset purchase agreement registrant osi pharmaceuticals inc dated november agreement plan merger among registrant simbolo acquisition sub inc whollyowned subsidiary registrant triangle pharmaceuticals inc dated december agreement plan merger among registrant gryphon acquisition sub inc corus pharma inc rodney ferguson phd chairman behalf stockholder representative committee dated april stock purchase agreement among registrant degussa ag laporte nederland bv raylo chemicals inc dated june agreement plan merger among registrant mustang merger sub inc myogen inc dated october restated certificate incorporation registrant amended certificate amendment restated certificate incorporation registrant certificate designation series junior participating preferred stock registrant amendment certificate designation series junior participating preferred stock registrant amended restated bylaws registrant amended restated december reference made exhibit exhibit exhibit exhibit amended restated rights agreement registrant chasemellon shareholder services llc dated october first amendment amended restated rights agreement registrant mellon investor services llc formerly known chasemellon shareholder services llc dated october table contents exhibit exhibit footnote number description document second amendment amended restated rights agreement registrant mellon investor services llc formerly known chasemellon shareholder services llc dated may indenture related convertible senior notes due registrant wells fargo bank national association trustee including form convertible senior note due dated april indenture related convertible senior notes due registrant wells fargo bank national association trustee including form convertible senior note due dated april registration rights agreement among registrant merrill lynch pierce fenner smith incorporated morgan stanley co incorporated banc america securities llc goldman sachs co inc dated april form indemnity agreement entered registrant directors executive officers form employee proprietary information invention agreement entered registrant certain officers key employees form employee proprietary information invention agreement entered registrant certain officers key employees revised september form option agreements used stock option plan letter agreement registrant iocbrega dated september registrants employee stock purchase plan amended july registrants stock option plan related agreements amended restated april amended january amended january registrants nonemployee directors stock option plan including form option agreement thereunder amended january amended january amendment agreement registrant iocbrega dated october amendment agreement registrant iocbrega dated december development license agreement among registrant f hoffmannla roche ltd hoffmannla roche inc dated september nexstar pharmaceuticals incs incentive stock plan adopted february amended nexstar pharmaceuticals incs director option plan adopted july license distribution agreement dainippon sumitomo pharma co ltd successor sumitomo pharmaceuticals co ltd registrant successor nexstar pharmaceuticals inc dated september settlement agreement registrant successor nexstar pharmaceuticals inc astellas pharma inc successor fujisawa usa inc liposome company inc dated august amendment dated april sumitomo pharmaceuticals co ltd registrant successor nexstar pharmaceuticals inc license distribution agreement dated september sumitomo registrant successor nexstar pharmaceuticals inc gilead sciences inc deferred compensation planbasic plan document table contents exhibitexhibit footnote number description document gilead sciences inc deferred compensation planadoption agreement addendum gilead sciences inc deferred compensation plan licensing agreement gilead world markets limited glaxo group limited dated april triangle pharmaceuticals inc stock incentive plan exclusive license agreement registrant successor triangle pharmaceuticals inc glaxo group limited wellcome foundation limited glaxo wellcome inc emory university dated may settlement agreement registrant successor triangle pharmaceuticals inc emory university dr david w barry glaxo wellcome plc glaxo wellcome inc glaxo group limited wellcome foundation limited dated may settlement exclusive license agreement registrant successor triangle pharmaceuticals inc shire biochem inc shire pharmaceuticals group plc emory university university georgia research foundation dated august master clinical commercial supply agreement gilead world markets ltd registrant patheon inc dated january licensing agreement registrant osi pharmaceuticals inc successor eyetech pharmaceuticals inc dated march amended may december april amendment licensing agreement eyetech pharmaceuticals inc registrant dated may amendment licensing agreement osi pharmaceuticals inc successor eyetech pharmaceuticals inc registrant dated december amendment licensing agreement osi pharmaceuticals inc successor eyetech pharmaceuticals inc registrant dated august amendment dated may licensing agreement dated april glaxo group limited gilead world markets limited license agreement japan tobacco inc registrant dated march tenofovir disoproxil fumarate manufacturing supply agreement gilead world markets ltd pharmachem technologies grand bahama ltd dated july royalty sale agreement among registrant emory university investors trust custodial services ireland limited solely capacity trustee royalty pharma dated july amended restated license agreement registrant emory university investors trust custodial services ireland limited solely capacity trustee royalty pharma dated july term loan agreement gilead biopharmaceutics ireland corporation lenders party thereto bank america na administrative agent dated december parent guaranty agreement registrant dated december favor bank america na connection term loan agreement subsidiary guaranty agreement gilead vintage park llc connection term loan agreement dated december table contents exhibitexhibit footnote number description document credit agreement registrant lenders party thereto bank america na administrative agent swing line lender lc issuer dated december subsidiary guaranty agreement gilead vintage park llc dated december connection credit agreement form employee stock option agreement used equity incentive plan form nonemployee stock option agreement used equity incentive plan gilead sciences inc corporate bonus plan first amendment supplement dated november development licensing agreement registrant f hoffmannla roche ltd hoffmanla roche inc dated september restated amended toll manufacturing agreement gilead sciences limited registrant altana pharma oranienburg gmbh dated november amended restated agreement registrant successor vestar inc astellas pharma inc successor fujisawa usa inc dated june gilead sciences inc severance plan amended may gilead sciences inc equity incentive plan amended may gilead sciences inc code section bonus plan gilead sciences inc deferred compensation plan confirmation otc convertible note hedge related notes dated april amended restated april registrant bank america na confirmation otc convertible note hedge related notes dated april amended restated april registrant bank america na confirmation otc warrant transaction dated april amended restated april registrant bank america na warrants expiring confirmation otc warrant transaction dated april amended restated april registrant bank america na warrants expiring emtricitabine manufacturing supply agreement gilead sciences limited degussa ag dated june corus pharma inc stock plan form corus pharma inc stock plan stock option agreement form restricted award agreement used equity incentive plan sixth amendment agreement license agreement institute organic chemistry biochemistry academy sciences czech republic k u leuven research development registrant dated august amended restated collaboration agreement among registrant gilead holdings llc bristolmyers squibb company er squibb sons llc bristolmyers squibb gilead sciences llc dated september base salaries named executive officers form performance share award agreement used equity incentive plan license agreement myogen inc abbott laboratories dated june table contents exhibit exhibit footnote number description document license agreement abbott deutschland holding gmbh company dated october license agreement myogen glaxo group limited dated march subsidiaries registrant consent independent registered public accounting firm power attorney reference made signature section certification section certification section certification filed exhibit registrants current report form k filed january incorporated herein reference filed exhibit registrants current report form k filed december incorporated herein reference filed exhibit registrants quarterly report form q quarter ended september incorporated herein reference filed exhibit registrants quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants current report form k filed october incorporated herein reference filed exhibit registrants registration statement form filed july incorporated herein reference filed exhibit registrants report form k filed may incorporated herein reference filed exhibit registrants report form k filed november incorporated herein reference filed exhibit registrants current report form k filed october incorporated herein reference filed exhibit registrants current report form k filed october incorporated herein reference filed exhibit registrants registration statement form filed june incorporated herein reference filed exhibit registrants current report form k filed april incorporated herein reference filed exhibit registrants registration statement form amended incorporated herein reference filed exhibit registrants fiscal year ended december incorporated herein reference filed exhibit registrants registration statement form filed january incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants annual report fiscal year ended march incorporated herein reference filed exhibit registrants fiscal year ended december incorporated herein reference filed exhibit nexstar pharmaceuticals incs quarterly report form q quarter ended june incorporated herein reference table contents filed exhibit nexstar pharmaceuticals incs form q quarter ended september incorporated herein reference filed exhibit nexstar pharmaceuticals incs fiscal year ended december incorporated herein reference filed exhibit nexstar pharmaceuticals incs form q quarter ended september incorporated herein reference filed exhibit nexstar pharmaceuticals incs form q quarter ended june incorporated herein reference filed exhibit registrants fiscal year ended december incorporated herein reference filed exhibit registrants quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants registration statement form filed january incorporated herein reference filed exhibit triangle pharmaceuticals incs quarterly report form q quarter ended september incorporated herein reference filed exhibit triangle pharmaceuticals incs current report form k filed september incorporated herein reference filed exhibit registrants fiscal year ended december incorporated herein reference filed exhibit registrants form q quarter ended march incorporated herein reference filed exhibit registrants form q quarter ended september incorporated herein reference filed exhibit registrants current report form k filed december incorporated herein reference filed exhibit registrants current report form k filed february incorporated herein reference filed exhibit registrants form q quarter ended march incorporated herein reference filed exhibit registrants registration statement form filed august incorporated herein reference filed exhibit registrants current report form k filed january incorporated herein reference filed exhibit myogen incs registration statement form amended originally filed august incorporated herein reference filed exhibit myogen incs quarterly report form q filed may incorporated herein reference management contract compensatory plan arrangement required filed pursuant item b certain confidential portions exhibit omitted means marking portions asterisk mark exhibit filed separately secretary sec without mark pursuant registrants application requesting confidential treatment rule b securities exchange act table contents gilead sciences inc consolidated financial statements years ended december contents report independent registered public accounting firm audited consolidated financial statements consolidated balance sheets consolidated statements operations consolidated statement stockholders equity consolidated statements cash flows notes consolidated financial statements table contents report independent registered public accounting firm board directors stockholders gilead sciences inc audited accompanying consolidated balance sheets gilead sciences inc december related consolidated statements operations stockholders equity cash flows three years period ended december audits also included financial statement schedule listed index item financial statements schedule responsibility companys management responsibility express opinion financial statements schedule based audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statements referred present fairly material respects consolidated financial position gilead sciences inc december consolidated results operations cash flows three years period ended december conformity us generally accepted accounting principles also opinion related financial statement schedule considered relation basic financial statements taken whole presents fairly material respects information set forth therein discussed note consolidated financial statements gilead sciences inc changed method accounting stockbased compensation accordance guidance provided statement financial accounting standards r sharebased payment also audited accordance standards public company accounting oversight board united states effectiveness gilead sciences incs internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission report dated february expressed unqualified opinion thereon ernst young llp palo alto california february table contents gilead sciences inc consolidated balance sheets thousands except per share amounts december assets current assets cash cash equivalents shortterm marketable securities accounts receivable net allowances december december inventories deferred tax assets prepaid expenses current assets total current assets property plant equipment net noncurrent portion prepaid royalties noncurrent deferred tax assets longterm marketable securities minority interest joint venture noncurrent assets total assets liabilities stockholders equity current liabilities accounts payable accrued clinical preclinical expenses accrued compensation employee benefits income taxes payable accrued liabilities deferred revenue current portion longterm obligations total current liabilities longterm deferred revenue convertible senior notes longterm obligations minority interest joint venture commitments contingencies stockholders equity preferred stock par value per share shares authorized none outstanding common stock par value per share shares authorized shares issued outstanding december respectively additional paidin capital accumulated comprehensive income deferred stock compensation retained earnings accumulated deficit total stockholders equity total liabilities stockholders equity see accompanying notes table contents gilead sciences inc consolidated statements operations thousands except per share amounts year ended december revenues product sales royalty revenue contract revenue total revenues costs expenses cost goods sold research development selling general administrative purchased inprocess research development total costs expenses income loss operations gain warrant makewhole payment convertible debt redemption interest income net interest expense minority interest joint venture income loss provision income taxes provision income taxes net income loss net income loss per sharebasic shares used per share calculationbasic net income loss per sharediluted shares used per share calculationdiluted see accompanying notes table contents gilead sciences inc consolidated statement stockholders equity thousands common stock accumulated retained additional deferred earnings total paidin comprehensive stock accumulated stockholders shares amount capital income loss compensation deficit equity balance december net income unrealized loss availableforsale securities net tax foreign currency translation adjustment unrealized loss cash flow hedges net tax comprehensive income conversion convertible senior notes net debt issuance costs issuances employee stock purchase plan stock option exercises net tax benefits employee stock plans amortization deferred stock compensation compensatory stock transactions balance december net income unrealized loss availableforsale securities net tax foreign currency translation adjustment unrealized gain cash flow hedges net tax comprehensive income issuances employee stock purchase plan stock option exercises net tax benefits employee stock plans amortization deferred stock compensation compensatory stock transactions balance december net loss unrealized gain availableforsale securities net tax foreign currency translation adjustment unrealized loss cash flow hedges net tax comprehensive loss issuances employee stock purchase plan stock option exercises net tax benefits employee stock plans reversal deferred stock compensation compensatory stock transactions assumption stock options connection acquisitions purchase convertible note hedges sale warrants deferred tax assets convertible note hedges repurchase common stock balance december see ac compan ing note table contents gilead sciences inc consolidated statements cash flows thousands year ended december operating activities net income loss adjustments reconcile net income loss net cash provided operating activities depreciation amortization purchased inprocess research development stockbased compensation expense excess tax benefits stockbased compensation tax benefits employee stock plans asset impairment gain warrant deferred income taxes writedown inventory minority interest joint venture otherthan temporary loss marketable securities noncash transactions changes operating assets liabilities accounts receivable net inventories prepaid royalties prepaid expenses assets accounts payable income taxes payable accrued liabilities deferred revenue minority interest joint venture net cash provided operating activities investing activities purchases marketable securities proceeds sales marketable securities proceeds maturities marketable securities acquisitions net cash acquired purchases nonmarketable equity securities capital expenditures net cash used investing activities financing activities proceeds issuances common stock proceeds term loan net issuance costs proceeds issuance convertible senior notes net issuance costs proceeds sale warrants purchase convertible note hedges repurchase common stock repayments longterm debt obligations excess tax benefits stockbased compensation net cash provided financing activities effect exchange rate changes cash net increase cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year supplemental disclosure cash flow information interest paid income taxes paid noncash investing financing activities common stock issued upon conversion debt reclassification achillion equity investment noncurrent assets marketable securities upon achillions initial public offering reclassification deferred debt issuance costs additional paidin capital upon conversion debt see accompanying notes table contents gilead sciences inc notes consolidated financial statements december organization summary significant accounting policies overview gilead sciences inc gilead incorporated delaware june biopharmaceutical company discovers develops commercializes innovative therapeutics areas unmet medical need mission advance care patients suffering lifethreatening diseases worldwide headquartered foster city california marketing operations north america europe australia date focused efforts bringing market novel therapeutics treatment lifethreatening infectious diseases expanded research development commercial focus include respiratory cardiopulmonary disease acquisition myogen inc myogen corus pharma inc corus currently market truvada emtricitabine tenofovir disoproxil fumarate viread tenofovir disoproxil fumarate atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate mg emtriva emtricitabine treatment human immunodeficiency virus hiv infection hepsera adefovir dipivoxil treatment chronic hepatitis b infection ambisome amphotericin b liposome injection treatment fungal infection vistide cidofovir injection treatment cytomegalovirus cmv infection flolan epoprostenol sodium treatment pulmonary hypertension f hoffmanla roche ltd together f hoffmanla roche inc roche markets tamiflu oseltamivir phosphate treatment influenza royalty paying collaborative agreement us manufacture macugen pegaptamib sodium injection manufacturing agreement osi pharmaceuticals inc osi sells macugen treatment neovascular agerelated macular degeneration royalty paying collaborative agreement us basis presentation accompanying consolidated financial statements include accounts gilead wholly owned subsidiaries joint venture bristolmyers squibb company bms primary beneficiary determined financial accounting standards board fasb interpretation consolidation variable interest entities fin r record minority interest consolidated financial statements reflect bmss interest joint venture significant intercompany transactions eliminated certain prior year amounts reclassified consistent current year presentation january began reporting net foreign exchange transaction gains losses well fair value changes derivative instruments designated hedges interest income net consolidated statements operations amounts million million years ended december respectively previously reported selling general administrative sga expenses reclassified conform current year presentation additionally began classifying interest receivable related marketable securities current assets consolidated balance sheets reclassification effect increasing current assets decreasing marketable securities million december consolidated statements cash flows years ended december reclassification effect decreasing net cash used investing activities decreasing net cash provided operating activities million million respectively reclassification affect consolidated statements operations result issuance convertible senior notes related transactions april see note cash cash equivalents marketable securities increased significantly net proceeds transactions considered together existing cash cash equivalents marketable securities credit facility see note anticipated significant cash outflows ability hold longterm marketable table contents gilead sciences inc notes consolidated financial statementscontinued december securities respective maturities significantly enhanced accordingly quarter ended june began prospectively classifying marketable securities portfolio shortterm longterm based contractual maturities significant accounting policies estimates judgments preparation consolidated financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis management evaluates estimates including related revenue recognition allowance doubtful accounts inventories prepaid royalties clinical trial accruals tax provision stockbased compensation base estimates historical experience various market specific relevant assumptions believed reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results may differ significantly estimates revenue recognition product sales recognize revenue product sales persuasive evidence arrangement exists delivery customer occurred price fixed determinable collectibility reasonably assured upon recognition revenue product sales provisions made government rebates customer incentives cash discounts prompt payment certain distributor fees estimated future returns products may expire appropriate items deducted gross product sales government rebates estimate amounts payable us governmentmanaged medicaid programs well certain qualifying federal state government programs based contractual terms historical utilization rates new information regarding changes programs regulations guidelines would impact amount actual rebates expectations regarding future utilization rates programs channel inventory data obtained major us wholesalers accordance inventory management agreements government rebates invoiced directly us recorded accrued liabilities consolidated balance sheets qualified programs purchase products wholesalers lower contractual government price wholesalers charge back us difference acquisition cost lower price record allowances accounts receivable cash discounts estimate cash discounts based contractual terms historical utilization rates expectations regarding future utilization rates distributor fees inventory management agreements significant us wholesalers pay wholesalers fee primarily compliance certain contractuallydetermined covenants maintenance agreedupon inventory levels distributor fees based contractuallydetermined fixed percentage sales table contents gilead sciences inc notes consolidated financial statementscontinued december product returns provide customers general right product return permit returns product damaged defective received customer product unites states expired accept product returns united states expired one year expiration estimates expected returns expired products based primarily ongoing analysis historical return patterns royalty revenue royalty revenue sales ambisome recognized month following month corresponding sales occur royalty revenue sales products recognized received quarter following quarter corresponding sales occur contract revenue contract revenue research development rd recorded performance occurs earnings process completed based performance requirements contract nonrefundable contract fees performance obligations exist continuing involvement gilead recognized earlier payments received collection reasonably assured revenue nonrefundable upfront license fees milestone payments continue involvement development collaboration obligation supply product recognized performance occurs obligations completed accordance specific terms gileads obligations types arrangements revenue recognized obligation fulfilled ratably development manufacturing period revenue associated substantive atrisk milestones recognized based upon achievement milestones defined respective agreements advance payments received excess amounts earned classified deferred revenue consolidated balance sheets contract revenue includes revenue product distribution services net recognized persuasive evidence arrangement exists delivery customer occurred price fixed determinable collectibility reasonably assured accordance emerging issues task force eitf issue reporting revenue gross principal versus net agent record product distribution services revenue net supply price paid manufacturerlicensor distribution fees paid specialty pharmacies allowances product returns cash discounts government rebates contract revenue consolidated statements operations shipping handling costs shipping handling costs incurred inventory purchases product shipments recorded cost goods sold consolidated statements operations research development expenses major components rd expenses consist personnel costs including salaries benefits stockbased compensation clinical studies performed clinical research organizations cros materials supplies licenses fees overhead allocations consisting various administrative facilities related costs rd activities also separated three main categories research clinical development pharmaceutical development research costs typically consist preclinical toxicology costs clinical development costs include costs phase clinical trials pharmaceutical development costs consist expenses incurred product formulation chemical analysis table contents gilead sciences inc notes consolidated financial statementscontinued december charge rd costs including clinical study costs expense incurred consistent statement financial accounting standards sfas accounting research development costs costs significant component rd expenses clinical studies performed thirdparty cros accrue costs clinical studies performed cros straightline basis service periods specified contracts adjust estimates required based upon going review level effort costs actually incurred cro monitor levels performance significant contract including extent patient enrollment activities communications cros adjust estimates required quarterly basis expenses reflect actual effort expended cro material cro contracts terminable us upon written notice generally liable actual effort expended cro point time contract regardless payment status amounts paid advance services performed refunded contract terminated contracts include additional termination payments become due payable terminate contract additional termination payments recorded contract terminated advertising expenses expense costs advertising including promotional expenses incurred advertising expenses million million million earnings loss per share basic earnings loss per share calculated based weightedaverage number shares common stock outstanding period diluted earnings loss per share calculated based weightedaverage number shares common stock dilutive securities outstanding period potential dilutive shares common stock resulting assumed exercise outstanding stock options equivalents assumed conversion convertible senior notes due notes convertible senior notes due notes collectively notes assumed exercise warrants relating notes determined treasury stock method following table reconciliation numerator denominator used calculation basic diluted earnings loss per share thousands year ended december numerator net income loss used calculation basic earnings loss per share interest expense makewhole payment convertible notes redemption net income loss used calculation diluted earnings loss per share denominator weightedaverage common shares outstanding used calculation basic earnings loss per share effect dilutive securities stock options equivalents convertible senior notes weightedaverage common shares outstanding used calculation diluted earnings loss per share table contents gilead sciences inc notes consolidated financial statementscontinued december stock options purchase approximately million million weightedaverage shares common stock also outstanding years ended december respectively included computation diluted earnings per share options exercise prices greater average market price common stock periods therefore effect antidilutive due net loss approximately million weightedaverage number outstanding stock options common stock equivalents included computation diluted net loss per share inclusion would antidilutive addition due inclusion restrictions conversion notes diluted earnings loss per share computation give effect dilution conversion notes share price common stock exceeds notes notes respectively stockbased compensation december fasb issued sfas revised sharebased payment sfas r revision sfas accounting stockbased compensation sfas requires sharebased payments employees directors including grants stock options recognized consolidated statement operations based fair values beginning first quarterly period first fiscal year beginning june early adoption permitted sfas r also requires benefit tax deductions excess recognized compensation cost reported statement cash flows financing cash flow rather operating cash flow sfas r supersedes accounting principles board opinion accounting stock issued employees apb amends sfas statement cash flows january adopted provisions sfas r requires fair value sharebased payments employees directors including grants stock options recognized consolidated statements operations applied modified prospective method one adoption methods permitted sfas r requires compensation expense recorded vesting nonvested stock options stockbased awards beginning first quarter adoption sfas r accordance modified prospective method prior period amounts restated reflect adoption sfas r addition calculated pool excess tax benefits available within additional paid capital apic accordance provisions sfas r table contents gilead sciences inc notes consolidated financial statementscontinued december pro forma information sfas prior adoption sfas r accordance provisions sfas amended sfas accounting stockbased compensationtransition disclosure elected follow apb fasb interpretation accounting certain transactions involving stock compensationan interpretation apb opinion accounting employee stockbased plans apb exercise price employee director stock options equal greater fair value underlying stock date grant compensation expense recognized consolidated statements operations table presents net income basic diluted net income per share compensation cost stock option plans espp determined based estimated fair value awards plans grant purchase date accordance sfas thousands except per share amounts year ended december net incomeas reported add stockbased employee compensation expense included reported net income net related tax effects deduct total stockbased employee compensation expense determined fair value based method awards net related tax effects net income used calculation basicpro forma earnings per share interest expense makewhole payment convertible debt redemption net income used calculation dilutedpro forma earnings per share net income per share basicas reported basicpro forma dilutedas reported dilutedpro forma cash cash equivalents consider highly liquid investments insignificant interest rate risk original maturity three months less purchase date cash equivalents may enter overnight repurchase agreements repos purchase securities obligation resell following day securities purchased agreements resell recorded face value reported cash cash equivalents investment policy may enter repos major banks authorized dealers provided repos collateralized us government securities fair value least fair value securities sold gilead eligible instruments investment policy included cash equivalents include commercial paper money market funds bank obligations marketable nonmarketable securities determine appropriate classification marketable securities consist primarily debt securities include auction rate securities variable rate demand obligations time purchase reevaluate designation balance sheet date marketable securities considered availableforsale carried estimated fair values reported either cash equivalents shortterm table contents gilead sciences inc notes consolidated financial statementscontinued december marketable securities longterm marketable securities unrealized gains losses availableforsale securities excluded earnings reported separate component stockholders equity interest income net includes interest dividends amortization purchase premiums discounts realized gains losses sales securities cost securities sold based specific identification method regularly review investments otherthantemporary declines fair value review includes consideration cause impairment including creditworthiness security issuers number securities unrealized loss position well severity duration unrealized losses determine decline fair value investment accounting basis otherthantemporary reduce carrying value securities hold record loss amount decline result entering collaborations time time may hold investments nonpublic companies record nonmarketable securities cost noncurrent assets less amounts otherthantemporary impairment regularly review investments indicators impairment investments nonmarketable securities material periods presented concentrations risk subject credit risk portfolio cash equivalents marketable securities policy limit amounts invested securities duration industry group investment type issuer except securities issued us government exposed significant concentrations credit risk financial instruments goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return also subject credit risk accounts receivable related product sales majority trade accounts receivable arises product sales united states europe certain countries payments typically slow primarily greece italy portugal spain aggregated accounts receivable balances significant cases slow payment practices countries reflect pace governmental entities reimburse customers turn may increase financial risk related certain customers sales customers countries tend relatively slow paying past increased future may increase average length time accounts receivable outstanding december past due accounts receivable greece italy portugal spain totaled million million days past due based contractual terms receivables december past due accounts receivable countries totaled million million days past due based contractual terms receivables date experienced significant losses respect collection accounts receivable believe past due accounts receivable net allowances reflected consolidated balance sheet collectible perform credit evaluations customers financial condition generally required collateral certain raw materials utilize operations obtained one supplier many raw materials utilize operations made one facility since suppliers key components raw materials must named new drug application nda filed us food drug administration fda product significant delays occur qualification new supplier required delivery material suppliers interrupted reason may unable ship truvada viread atripla emtriva hepsera ambisome vistide supply drug candidates clinical trials table contents gilead sciences inc notes consolidated financial statementscontinued december accounts receivable trade accounts receivable recorded net allowances government chargebacks cash discounts prompt payment doubtful accounts sales returns estimates government chargebacks cash discounts sales returns based contractual terms historical trends expectations regarding utilization rates programs estimates allowance doubtful accounts determined based existing contractual obligations historical payment patterns customers individual customer circumstances analysis days sales outstanding customer geographic region review local economic environment potential impact government funding reimbursement practices historically amounts uncollectible accounts receivable written insignificant consistent managements expectations inventories inventories recorded lower cost market cost determined firstin firstout basis periodically review composition inventory order identify obsolete slowmoving otherwise unsaleable items unsaleable items observed alternate uses inventory record writedown net realizable value period impairment first recognized prepaid royalties prepaid royalties capitalized cost based present value future royalty obligation would expect pay licensor expected levels product sales incorporating related technology review quarterly expected future sales levels products indicators might require writedown net recoverable value assets change estimated life prepaid royalty amortize prepaid royalties cost goods sold remaining life underlying patent based effective royalty rate derived forecasted future product sales incorporating related technology review effective royalty rate least annually prospectively adjust effective rate based significant new facts circumstances may arise review property plant equipment property plant equipment stated cost less accumulated depreciation amortization depreciation amortization recognized using straightline method land depreciated repairs maintenance costs expensed incurred estimated useful lives years follows description estimated useful life buildings improvements laboratory manufacturing equipment office computer equipment leasehold improvements shorter useful life lease term office computer equipment includes capitalized computer software capitalized software purchased internally developed computer software leasehold improvements capitalized leased equipment amortized shorter lease term assets useful life amortization capitalized leased equipment included depreciation expense capitalized interest construction inprogress included property plant equipment interest million capitalized significant interest capitalized table contents gilead sciences inc notes consolidated financial statementscontinued december goodwill intangible assets goodwill represents excess purchase price estimated fair value net assets acquired business combination accordance sfas goodwill intangible assets sfas goodwill amortized required tested annually impairment test goodwill impairment annual basis annual tests become aware events occurring changes circumstances would indicate reduction fair value goodwill carrying amount accordance sfas intangible assets definite lives amortized estimated useful lives reviewed impairment facts circumstances suggest carrying value assets may recoverable impairment longlived assets carrying value longlived assets reviewed regular basis existence facts circumstances internally externally may suggest impairment specific potential indicators impairment include significant decrease fair value asset significant change extent manner asset used significant physical change asset significant adverse change legal factors business climate affects value asset adverse action assessment fda another regulator accumulation costs significantly excess amount originally expected acquire construct asset operating cash flow losses combined history operating cash flow losses projection forecast demonstrates continuing losses associated incomeproducing asset indication impairment test recoverability comparing estimated undiscounted future cash flows expected result use asset eventual disposition carrying amount asset estimating future cash flows assets liabilities grouped lowest level identifiable cash flows largely independent cash flows generated groups undiscounted future cash flows less carrying amount asset impairment loss measured excess carrying value asset estimated fair value recognized cash flow estimates used calculations based managements best estimates using appropriate customary assumptions projections time foreign currency translation transactions contracts adjustments resulting translating financial statements foreign subsidiaries us dollars excluded determination net income loss accumulated separate component stockholders equity net foreign exchange transaction gains losses included interest income net consolidated statements operations realized gains losses totaled million million million respectively hedge certain foreign currency exposures related outstanding trade accounts receivable forecasted product sales foreign exchange forward contracts general market risks contracts offset corresponding gains losses transactions hedged exposure credit risk contracts function changes interest currency exchange rates therefore varies time limit risk counterparties contracts may unable perform transacting major banks also limit risk loss entering contracts provide net settlement maturity therefore overall risk loss event counterparty default limited amount unrecognized unrealized gains outstanding contracts ie contracts positive fair value date table contents gilead sciences inc notes consolidated financial statementscontinued december default enter speculative foreign currency transactions presently hedge net investment foreign subsidiaries accounting hedges net monetary assets liabilities record changes fair value interest income net derivative instruments designated hedges sfas nos accounting derivative instruments hedging activities collectively referred sfas selectively hedge anticipated currency exposures purchasing forward contracts hedge anticipated product sales next year less designated cash flow hedges sfas unrealized gains losses underlying forward contracts recorded comprehensive income loss recognized earnings forecasted transaction occurs december december net unrealized gains losses million million respectively open foreign exchange forward contracts gains losses cash flow hedges recorded product sales increased decreased product sales million million million respectively notional amounts forward exchange contracts outstanding billion december million december asset liability fair value million million december respectively contracts maturities one year less see note discussion derivative financial instruments fair value financial instruments financial instruments consist principally cash cash equivalents marketable securities accounts receivable certain noncurrent assets forward foreign exchange contracts accounts payable longterm debt longterm obligations cash cash equivalents marketable securities see note forward foreign exchange contracts hedge accounts receivable see note reported respective fair values balance sheet forward foreign exchange contracts hedge forecasted sales recorded fair value net related deferred gain loss resulting reported net balance zero believe remaining financial instruments reported consolidated balance sheets amounts approximate current fair values income taxes income tax provision computed liability method deferred tax assets liabilities determined based difference financial statement tax basis assets liabilities using enacted tax rates effect year differences expected reverse significant estimates required determining provision income tax estimates based interpretations existing tax laws regulations believe estimates reasonable reserves income taxrelated uncertainties adequate various internal external factors may favorable unfavorable effects future effective income tax rate factors include limited interpretations existing tax laws adoption sfas r relating accounting stock options sharebased compensation changes tax laws rates mergers acquisitions future levels research development spending changes accounting standards future levels capital expenditures changes mix earnings various tax jurisdictions operate changes overall levels pretax earnings finalization federal state income tax audits table contents gilead sciences inc notes consolidated financial statementscontinued december recent accounting pronouncement june fasb issued fasb interpretation accounting uncertainty income taxes fin interpretation sfas accounting income taxes sfas fin clarifies accounting uncertainty income taxes recognized enterprises financial statements accordance sfas prescribing minimum recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return fin also provides guidance derecognition measurement classification interest penalties accounting interim periods disclosure transition fin effective fiscal years beginning december adopted fin january required preliminary determination impact adopting standard range million million actual amount recorded charge accumulated deficit consolidated balance sheet upon adoption fin derivative financial instruments derivatives recognized either assets liabilities measured fair value enter foreign currency forward contracts hedge changes fair value significant monetary assets liabilities denominated nonfunctional currency derivative designated meets definition fair value hedge changes fair value derivative hedged item recognized earnings enter foreign currency forward contracts maturities months less hedge future cash flows related forecasted product sales foreign denominated currencies derivative instruments employed eliminate minimize certain foreign currency exposures confidently identified quantified hedges related forecasted foreign currency product sales designated documented inception respective hedge designated cash flow hedges evaluated effectiveness monthly terms forward contract underlying transaction matched inception forward contract effectiveness calculated comparing fair value contract estimated change fair value underlying hedged item effective component hedge recorded accumulated comprehensive income see note substantially values reported accumulated comprehensive income december reclassified earnings within months residual changes fair value instruments including resulting cancellation dedesignation hedge contracts ineffectiveness recognized immediately interest income net impact ineffectiveness significant consolidated statements operations gains losses million million million hedging contracts recognized consolidated statements operations respectively included cash provided operating activities consolidated statements cash flows result entering collaboration arrangement held warrants purchase stock nonpublic company completed initial public offering january see notes warrants exercised end first quarter acquisitions myogen inc november completed acquisition outstanding shares common stock myogen via cash tender offer terms agreement plan merger entered october merger agreement myogen publiclyheld biopharmaceutical company based westminster table contents gilead sciences inc notes consolidated financial statementscontinued december colorado focused discovery development commercialization small molecule therapeutics treatment cardiovascular disorders myogen two product candidates latestage clinical development ambrisentan treatment patients pulmonary arterial hypertension darusentan treatment patients resistant hypertension believe acquisition provide us opportunity expand respiratory cardiopulmonary therapeutic area initially established acquisition corus august myogen acquisition accounted business combination accordance sfas business combinations sfas results operations myogen since november included consolidated statement operations primarily consist rd sga expenses aggregate purchase price myogens common stock billion consisted cash paid prior closing billion fair value vested stock options assumed million estimated direct transaction costs million consist primarily investment banking fees employeerelated severance costs million employeerelated severance costs included part purchase price established workforce reduction plan part acquisition transaction accordance eitf issue recognition liabilities connection purchase business combination eitf accordance merger agreement entered myogen conversion value stock option assumed determined based exercise price option purchase shares common stock myogen average closing price common stock five consecutive trading days immediately preceding including tender offer acceptance date november per share estimated fair value stock options assumed determined using average price per share approximated price would resulted averaging closing price common stock two trading days two trading days acceptance date accordance eitf issue determination measurement date market price acquirer securities issued purchase business combination fair value stock options assumed calculated using blackscholes valuation model following assumptions expected life ranging years riskfree interest rate ranging expected volatility ranging dividend yield fair value asconverted gilead stock options exceed fair value myogen stock options immediately prior exchange approximately million million asconverted shares subject outstanding myogen stock options fully vested estimated fair value vested options million included purchase price estimated fair value unvested options million included purchase price recognized compensation expense remaining future vesting period options table contents gilead sciences inc notes consolidated financial statementscontinued december following table summarizes preliminary purchase price allocation november thousands cash cash equivalents shortterm marketable securities accounts receivable net prepaid expenses assets accounts payable deferred revenue liabilities net tangible assets deferred tax assets purchased inprocess research development goodwill total purchase price million deferred revenue reflects fair value deferred revenue legal performance obligations accordance eitf issue accounting business combination deferred revenue acquiree million deferred tax assets primarily related federal net operating loss tax credit carryforwards certain state amortizations concluded based standard set forth sfas likely realize benefits deferred tax assets elected treat myogen acquisition asset acquisition california state tax purposes purchased inprocess research development iprd goodwill resulting acquisition deductible california state income tax purposes although amounts deductible federal income tax purposes purchase price allocation preliminary finalized continuing review amount federal net operating loss carryforwards available us assessing tax deductibility certain acquisitionrelated transaction costs accordance sfas eitf issue uncertainties related income taxes purchase business combination material changes preliminary allocation summarized reported related uncertainties resolved estimated fair value purchased iprd billion determined management management considered number factors determining value iprd including results independent valuation performed third party valuation specialist purchased iprd represents myogens incomplete research development programs yet reached technological feasibility alternative future uses acquisition date therefore expensed upon acquisition within consolidated statements operations summary iprd programs acquisition date follows estimated acquisition date fair value program description status development millions ambrisentan orally active nonsulfonamide propanoic acidclass endothelin phase clinical trials completed prior acquisition date filed nda receptor antagonist era treatment pulmonary arterial fda december february fda granted us priority review hypertension status nda marketing approval ambrisentan established target review date june table contents gilead sciences inc notes consolidated financial statementscontinued december estimated acquisition date fair value program description status development millions darusentan orally active etaselective era treatment resistant phase clinical development acquisition date date filing hypertension estimated fair value purchased iprd determined using income approach discounts expected future cash flows present value estimated related future net cash flows using present value riskadjusted discount rate significant assumption based estimated internal rate return myogens operations comparable estimated weighted average cost capital companies myogens profile projected cash flows ambrisentan darusentan programs based key assumptions estimates revenues operating profits related programs considering stages development time resources needed complete development approval related product candidates life potential commercialized products associated risks including inherent difficulties uncertainties developing drug compound obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets remaining efforts completion myogens iprd projects primarily consist clinical trials cost length success extremely difficult predict obtaining necessary regulatory approvals numerous risks uncertainties exist could prevent completion development including ability enroll patients clinical trials possibility unfavorable results clinical trials risk failing obtain fda regulatory body approvals feedback regulatory authorities results clinical trials might require modifications delays later stage clinical trials additional trials performed certain either ambrisentan darusentan purchased myogen approved united states countries outside united states whether marketing approvals significant limitations use future discussions regulatory agencies determine amount data needed timelines review may differ materially current projections acquired product candidates development may never successfully commercialized result may make strategic decision discontinue development product candidates example believe commercialization difficult relative opportunities pipeline programs completed timely basis prospects future revenue growth may adversely impacted assurance given underlying assumptions used forecast cash flows timely successful completion projects materialize estimated reasons among others actual results may vary significantly estimated results excess purchase price fair value amounts assigned assets acquired liabilities assumed million represents goodwill amount resulting myogen acquisition recorded goodwill noncurrent asset consolidated balance sheet acquisition date accordance sfas test goodwill impairment annual basis annual tests become aware events occurring changes circumstances would indicate reduction fair value goodwill carrying amount following unaudited pro forma information presents results operations gilead myogen years ended december acquisition myogen completed january respectively unaudited pro forma results include nonrecurring charge purchased table contents gilead sciences inc notes consolidated financial statementscontinued december iprd period presented resulted directly transaction unaudited pro forma results reflect operating efficiencies potential cost savings may result consolidation operations gilead myogen accordingly unaudited pro forma results presented illustrative purposes intended represent indicative actual results operations combined company would achieved acquisition occurred beginning period presented intended represent indicative future results operations unaudited pro forma results operations follows thousands except per share data year ended december total revenues net loss net loss per sharebasic diluted raylo chemicals inc november completed acquisition outstanding shares common stock raylo chemicals inc raylo whollyowned subsidiary germanybased specialty chemicals company degussa ag located edmonton canada raylos operations encompass custom manufacturing active pharmaceutical ingredient api advanced intermediates pharmaceutical biopharmaceutical industries intend utilize raylo site process research scaleup clinical development candidates manufacture api investigational commercial products chemical development activities improve existing commercial manufacturing processes raylo acquisition accounted business combination accordance sfas results operations raylo since november included consolidated statement operations primarily consist contract revenue cost goods sold clinical api expense aggregate purchase price raylos common stock million consisted cash paid prior closing million estimated direct transaction costs million employeerelated severance costs million employeerelated severance costs included part purchase price established workforce reduction plan part acquisition transaction accordance eitf costs fully paid december following table summarizes purchase price allocation november thousands net tangible assets gmp qualification intangible asset goodwill total purchase price million net tangible assets includes million cash million property plant equipment million tangible assets less assumed liabilities million estimated fair value million associated good manufacturing practices gmp qualification raylos facilities determined management based part results independent valuation performed table contents gilead sciences inc notes consolidated financial statementscontinued december thirdparty valuation specialist value recorded intangible asset amortized straightline basis three years estimated useful life asset determined management based amount time would derive benefit making substantial upgrades revisions acquired manufacturing practices december accumulated amortization asset million also represents amortization expense recognized date acquisition december estimated aggregate amortization expense recognized future years approximately million million excess purchase price fair value amounts assigned assets acquired liabilities assumed million represents goodwill amount resulting raylo acquisition recorded goodwill noncurrent asset consolidated balance sheet acquisition date accordance sfas test goodwill impairment annual basis annual tests become aware events occurring changes circumstances would indicate reduction fair value goodwill carrying amount elected treat raylo acquisition asset acquisition federal california state tax purposes goodwill resulting acquisition deductible federal california state income tax purposes prior acquisition raylo one longstanding contract manufacturers determined accordance eitf issue accounting preexisting relationships parties business combination settlement preexisting relationship part business combination value needed assigned preexisting relationship purchase price allocation summarized raylos assets acquisition date included million trade receivables us eliminated consolidated financial statements upon completion acquisition consider raylo acquisition material business combination sfas therefore disclosed pro forma results operations required sfas material business combinations corus pharma inc august completed acquisition corus privatelyheld biopharmaceutical company based seattle washington corus development stage company focused development commercialization novel drugs respiratory infectious diseases corus one lead product candidate latestage clinical trials two earlystage product candidates acquisition provides us opportunity expand respiratory therapeutic area augments pipeline corus acquisition accounted acquisition assets rather business combination accordance criteria outlined eitf issue determining whether nonmonetary transaction involves receipt productive assets business sfas corus considered development stage company commenced planned principal operations additionally lacked necessary elements business including completed product therefore ability access customers results operations corus since august included consolidated statement operations primarily consist rd expenses lesser extent sga expenses april purchased million coruss series c preferred stock represented approximately coruss voting equity interests time conjunction purchase series c table contents gilead sciences inc notes consolidated financial statementscontinued december preferred stock also entered agreement plan merger option acquire merger remaining outstanding shares corus july announced agreed exercise option concurrently entered agreement novartis vaccines diagnostics inc novartis whereby novartis agreed dismiss litigation corus payment made us novartis since claims made novartis directly implicated coruss right develop commercialize products settling novartis deemed appropriate allow completion acquisition ensure claims novartis could impede ability develop commercialize corus product candidates without settlement results ongoing trial time settlement would uncertain sustained period following closing due legal appeals potential proceedings upon completion acquisition included investment coruss series c preferred stock payment novartis part acquisition purchase price aggregate purchase price acquired shares assets million consisted cash paid prior closing million fair value vested stock options assumed million estimated direct transaction costs million employeerelated severance costs million addition holdback amount million payable corus shareholders us future except extent utilized pay claims made us within one year closing merger assessed probable pay holdback amount therefore recorded amount accrued liabilities consolidated balance sheet acquisition date employeerelated severance costs included part purchase price established workforce reduction plan part acquisition transaction following table summarizes purchase price allocation august thousands net tangible assets assembled workforce net deferred tax assets purchased inprocess research development million net tangible assets includes million cash million investments million tangible assets less assumed liabilities million million value assigned assembled workforce amortized three years estimated useful life asset million net deferred tax assets primarily related federal net operating loss tax credit carryforwards certain state amortizations concluded based standard set forth sfas likely realize benefits deferred tax assets elected treat corus acquisition asset acquisition california state tax purposes purchased iprd resulting acquisition deductible california state income tax purposes although amount deductible federal income tax purposes estimated fair value purchased iprd assembled workforce determined management management considered number factors determining value iprd including results independent valuation performed thirdparty valuation specialist estimated fair value purchased iprd greater purchase price paid therefore amount allocated purchased iprd consists net amount remaining allocating purchase price net tangible assets assembled workforce net deferred tax assets purchased iprd represents coruss incomplete research table contents gilead sciences inc notes consolidated financial statementscontinued december development program yet reached technological feasibility alternative future use acquisition date therefore expensed upon acquisition within consolidated statement operations summary program acquisition date follows estimated acquisition date fair value program description status development millions inhaled aztreonam lysine cystic fibrosis aztreonam formulation inhalation used gramnegative phase clinical trials acquisition date date filing bacteria cause lung infections patients cystic fibrosis estimated fair value purchased iprd determined using income approach discounts expected future cash flows present value estimated related future net cash flows using present value riskadjusted discount rate significant assumption based estimated internal rate return coruss operations comparable estimated weighted average cost capital companies coruss profile projected cash flows aztreonam lysine inhalation program based key assumptions estimates revenues operating profits related program considering stage development time resources needed complete development approval related product candidate life potential commercialized product associated risks including inherent difficulties uncertainties developing drug compound obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets coruss two earlystage candidates included valuation purchased iprd earlystage projects identifiable revenues expenses associated remaining efforts completion coruss iprd project primarily consist clinical trials cost length success extremely difficult predict obtaining necessary regulatory approvals numerous risks uncertainties exist could prevent completion development including ability enroll patients clinical trials possibility unfavorable results clinical trials risk failing obtain fda regulatory body approvals feedback regulatory authorities results clinical trials might require modifications delays later stage clinical trials additional trials performed certain aztreonam lysine cystic fibrosis purchased corus approved united states countries outside united states whether marketing approvals significant limitations use future discussions regulatory agencies determine amount data needed timelines review may differ materially current projections acquired product candidate development may never successfully commercialized result may make strategic decision discontinue development product candidate example believe commercialization difficult relative opportunities pipeline program completed timely basis prospects future revenue growth may adversely impacted assurance given underlying assumptions used forecast cash flows timely successful completion project materialize estimated reasons among others actual results may vary significantly estimated results acquisition real estate august completed purchase two additional buildings located foster city california campus aggregate purchase price million purchase price allocated table contents gilead sciences inc notes consolidated financial statementscontinued december land buildings land improvements based estimated relative fair values determined management based part independent appraisal million million million respectively fair value buildings land improvements depreciated remaining useful economic lives estimated years asset disposal march received local city approval proceed demolition two buildings foster city california begin construction new facilities included charge associated writeoff buildings equal aggregate net book value million sga expenses gain warrant march entered agreement eyetech pharmaceuticals inc eyetech predecessor osi relating proprietary aptamer eye currently known macugen pursuant agreement received warrant purchase shares eyetech series b convertible preferred stock exercisable price per share january eyetech completed initial public offering common stock time adjusted carrying value warrant estimated fair value resulting gain million included consolidated statement operations year ended december fair value warrant estimated using blackscholes valuation model volatility discount rate end first quarter exercised warrant net basis using shares eyetech common stock consideration exercise price subsequently held shares eyetech common stock second quarter sold eyetech shares held realized gain million included interest income net consolidated statement operations year ended december table contents gilead sciences inc notes consolidated financial statementscontinued december availableforsale securities following summary availableforsale securities recorded cash equivalents marketable securities consolidated balance sheets estimated fair values availableforsale securities based prices obtained commercial pricing services thousands gross gross amortized unrealized unrealized estimated cost gains losses fair value december debt securities us treasury securities us government sponsored entity debt securities corporate debt securities assetbacked securities municipal debt securities debt securities total debt securities equity securities total december us treasury securities obligations us government agencies us government sponsored entity debt securities corporate debt securities assetbacked securities municipal debt securities debt securities total december debt securities consisted primarily money market funds auction rate securities following table presents classification availableforsale securities consolidated balance sheets december cash cash equivalents shortterm marketable securities longterm marketable securities total december portfolio availableforsale debt securities comprised million securities contractual maturity less one year million securities contractual maturity greater one year less five years auction rate securities aggregate fair value million contractual maturities greater ten years table contents gilead sciences inc notes consolidated financial statementscontinued december following table presents certain information related sales marketable securities thousands year ended december proceeds sales gross realized gains sales gross realized losses sales december following availableforsale debt securities continuous unrealized loss position deemed otherthantemporarily impaired thousands less months months greater gross gross unrealized estimated unrealized estimated losses fair value losses fair value december us treasury securities us government sponsored entity debt securities corporate debt securities assetbacked securities municipal debt securities total december us treasury securities us government sponsored entity debt securities corporate debt securities assetbacked securities municipal debt securities total gross unrealized losses caused interest rate increases significant facts circumstances arisen indicate deterioration creditworthiness issuers securities based review securities including assessment duration severity related unrealized losses ability intent hold investments maturity otherthantemporary impairments securities december european headquarters relocation june announced commercial medical administrative groups european headquarters based paris france would relocated london area united kingdom european headquarters regulatory safety information technology groups already located cambridge area united kingdom believe relocation enable us achieve efficiencies closer proximity groups position ourself compete large pharmaceutical companies global level french subsidiary continues occupy existing paris facilities continue maintain expand sales marketing presence france table contents gilead sciences inc notes consolidated financial statementscontinued december third quarter relocation plans finalized accrued charge million primarily consisting employee severance costs termination benefits included sga expenses december majority severance costs termination benefits paid thereby reducing relocation accrual included accrued compensation employee benefits consolidated balance sheets insignificant amount additional costs relating new headquarters united kingdom including recruitment costs legal expenses capital expenditures related costs expensed incurred significant relocation activities completed december aggregate severance relocation recruiting costs resulting relocation european headquarters approximately million inventories inventories summarized follows thousands december work process raw materials finished goods total december joint venture formed gilead bms included consolidated financial statements held million million respectively sustiva efavirenz api purchased bms bmss estimated net selling price sustiva us market included inventory see note established gilead access program december pursuant agreed make truvada viread available noprofit prices developing countries africa caribbean latin america southeast asia based regular evaluation forecasted sales pricing inventory shelf life concluded would fully recover full carrying value associated inventory truvada viread gilead access program result recorded million year ended december cost goods sold writedown inventory estimated net realizable value table contents gilead sciences inc notes consolidated financial statementscontinued december consolidated balance sheet detail thousands december property plant equipment net buildings improvements including leasehold improvements laboratory manufacturing equipment office computer equipment capitalized leased equipment construction inprogress less accumulated depreciation amortization including relating capitalized leased equipment respectively subtotal land total accrued liabilities accrued medicaid rebates liabilities total joint venture bristolmyers squibb december entered collaboration bms develop commercialize single tablet regimen truvada bmss sustiva united states structured joint venture bms formed limited liability company bristolmyers squibb gilead sciences llc terms collaboration bms granted royaltyfree sublicenses joint venture use respective companyowned technologies return granted license joint venture use intellectual property results collaboration ownership interests joint venture bms us reflect respective economic interests based fraction estimated net selling price atripla single tablet regimen attributable truvada sustiva respectively adjusted annual basis since net selling price truvada may change time relative net selling price sustiva gileads bmss respective economic interests joint venture may vary annually primary responsibility clinical development activities regulatory filings relating new products resulting collaboration share marketing sales efforts bms parties provide equivalent sales force efforts minimum number years daily operations joint venture governed four primary joint committees responsible accounting financial reporting product distribution joint venture parties agree provide respective bulk api joint venture approximate market values april joint venture filed nda fda approval atripla treatment hiv infection adults july joint venture received approval atripla september bms amended joint ventures collaboration agreement allow joint venture sell atripla canada december joint venture held sustiva api purchased bms bmss estimated net selling price sustiva us market included inventory consolidated balance sheets see note table contents gilead sciences inc notes consolidated financial statementscontinued december joint ventures total equity investment risk expected sufficient allow finance operational activities without ongoing funding bms us although primary beneficiary legal structure joint venture limits recourse creditors general credit assets explained note consolidated financial statements include accounts joint venture bms reflect bmss minority interest joint venture collaborative arrangements contracts result entering strategic collaborations time time may hold investments nonpublic companies review interests investee companies consolidation andor appropriate disclosure provisions fin r december determined certain investee companies variable interest entities however respect joint venture bms primary beneficiary roche september entered development license agreement agreement f hoffmannla roche ltd hoffmannla roche inc together roche develop commercialize therapies treat prevent viral influenza tamiflu antiviral oral formulation treatment prevention influenza codeveloped us roche agreement roche exclusive right manufacture sell tamiflu worldwide subject obligation pay us percentage net revenues roche generates tamiflu sales turn subject reduction certain defined manufacturing costs june delivered notice termination roche material breach agreement november resolved dispute roche relating breach agreement agreed terminate related arbitration pending parties connection dispute resolution entered first amendment supplement agreement roche amended agreement provides formation joint manufacturing committee review roches existing manufacturing capacity tamiflu global plans manufacturing tamiflu us commercial committee evaluate commercial plans strategies tamiflu united states joint supervisory committee evaluate roches overall commercial plans tamiflu global basis case consisting representatives roche us amended agreement also option provide specialized sales force supplement roches marketing efforts united states tamiflu royalties payable us net sales tamiflu sold roche remain amended agreement follows first million worldwide net sales given calendar year b next million worldwide net sales calendar year c worldwide net sales excess million calendar year amended agreement revised provision agreement relating calculation royalty payments given calendar quarter roche pay royalties based actual royalty rates applicable quarter addition amended agreement royalties payable roche us longer subject cost goods sold adjustment provided agreement roche paid us million recognized royalty revenues consisting million relating disputed royalties million relating reimbursement cost goods adjustment million relating updating royalties payable us first nine months based thencurrent royalty rates instead prior years effective royalty rate table contents gilead sciences inc notes consolidated financial statementscontinued december recorded total million million million tamiflu royalties respectively recognize royalty revenue roche quarter following quarter related tamiflu sales occur recognized contract revenue million milestone payment japanese approval tamiflu prophylaxis last milestones receivable amended agreement emory university july royalty pharma purchased royalty interest owned emory university emory emtricitabine hiv indication terms agreement royalty pharma paid respectively total purchase price million emory exchange elimination emtricitabine royalties due emory worldwide net sales product containing emtricitabine result transaction capitalized prepaid royalties share million purchase price million amortize prepaid royalty cost goods sold remaining life underlying patent based effective royalty rate derived forecasted future product sales million million amortized cost goods sold respectively record royalties royalty pharma based actual emtricitabine net sales relative royalty pharmas ownership underlying emory royalty interest paid royalties million million royalty pharma respectively july made payment million emory connection amendment restatement existing license agreement emory providing us greater strategic flexibility development emtricitabine hepatitis b indication recorded payment rd expenses expecting significant related rd next several years prior july paid royalties emory respect emtricitabine hiv indication worldwide license acquired acquisition triangle pharmaceuticals inc triangle paid royalties million million respectively net sales emtricitabine iocbrega entered agreements institute organic chemistry biochemistry academy sciences czech republic rega stichting iocbrega relating certain nucleotide compounds discovered two institutions agreements received exclusive right manufacture use sell nucleotide compounds obligated pay iocbrega percentage net revenues received sales products containing patented compounds subject minimum royalty payments products covered original agreement included vistide hepsera viread december agreements iocbrega amended provide reduced royalty rate future sales products containing tenofovir adefovir return upfront payment us million upon signing agreement payment recorded prepaid royalty classified assets consolidated balance sheets prepaid royalty recognized royalty expense expected commercial life tenofovir adefovir amortization million payment began product launch dates viread hepsera december million remained amortized august agreements iocbrega amended include truvada future fixeddose combination products contain licensed technology make quarterly payments iocbrega based percentage vistide hepsera viread truvada net sales iocbrega agreed waive table contents gilead sciences inc notes consolidated financial statementscontinued december right royalty sales truvada viread developing countries sell products profit gilead access program sales atripla distributed merck co inc developing countries paid royalties million million million iocbrega respectively japan tobacco inc july entered licensing agreement japan tobacco inc japan tobacco japan tobacco would commercialize products hiv product portfolio japan agreement includes viread truvada emtriva terms agreement received upfront license fee million received additional payments upon achievement certain milestones japan tobacco pay us royalty net sales products japan upfront license fee recorded deferred revenue amortized contract revenue period supply products japan tobacco approximately eleven years remaining december received million year milestone payments japan tobacco related japanese regulatory approval marketing authorization viread emtriva truvada amortizing remaining period upfront license fee march entered licensing agreement japan tobacco japan tobacco granted us exclusive rights develop commercialize novel hiv integrase inhibitor gs formerly known jtk countries world excluding japan japan tobacco retained rights terms agreement incurred upfront license fee million included rd expenses first quarter future alternative use technology march recorded million rd expenses related milestone incurred result dosing first patient phase clinical study obligated make additional payments upon achievement milestones well pay royalties based future net product sales territories may market drug achillion pharmaceuticals november entered exclusive license collaboration agreement achillion pharmaceuticals inc achillion terms agreement granted worldwide rights research development commercialization certain small molecule hepatitic c virus hcv replication inhibitors involving hcv protease treatment hepatitis c collaboration achillion obligated continue development inhibitor compounds according mutually agreed upon development plan completion proofofconcept clinical study hcvinfected patients costs incurred achieve proofofconcept shared equally achillion us costs incurred us amounted million million respectively following proofofconcept study obligated assume full responsibilities incur costs associated development commercialization compounds warranting development achillion option participate us commercialization efforts future products arising collaboration conjunction signing collaboration paid million upfront license fee recorded rd expense future alternative use licensed technology additionally invested achillions convertible preferred stock agreed make payments achillion upon achievement certain milestones outlined agreement well pay royalties future net sales products arising collaboration october achillion completed initial public offering convertible preferred stock converted shares achillion common stock december investment achillions common stock million recorded longterm marketable securities december achillion began dosing hcvinfected table contents gilead sciences inc notes consolidated financial statementscontinued december patients phase clinical study gs also known ach treatment hepatitis c february based preliminary data phase b study companies decided discontinue development gs genelabs technologies inc september entered license research collaboration agreement genelabs technologies inc genelabs research develop commercialize certain genelabss novel nucleoside inhibitors hcv polymerase treatment chronic infection caused hcv conjunction signing agreement paid million upfront license fee recorded rd expense future alternative use technology initially agreed upon term three years genelabs obligated lead research efforts option extend research term collaboration additional year lead development commercialization activities agreed provide annual funding full time equivalents made million million respectively payments genelabs recorded rd expense obligated make additional payments upon achievement certain milestones pay royalties future net sales selected compounds developed approved relation collaboration medarex inc july entered agreement medarex inc medarex medarex would buyout future royalty obligations us approved products result medarexs licensing patent estate previously held nexstar inc total amount due us agreement million received two installments totaling million four installments totaling million final two installments totaling million recorded contract revenue glaxosmithkline inc april entered licensing agreement gsk providing gsk right commercialize hepsera oral antiviral treatment chronic hepatitis b asia latin america certain territories agreement retained rights hepsera united states canada europe australia new zealand turkey gsk received exclusive rights develop hepsera solely treatment chronic hepatitis b territories significant include china japan republic korea taiwan received million milestone payment gsk us approval hepsera million milestone payment canadian approval hepsera aggregate million milestone payments commercial approvals hepsera japan republic korea taiwan received aggregate million milestone payments gsk achievement gsk four consecutive quarters hepsera gross sales exceeding million achievement certain drug status china gsk full responsibility development commercialization hepsera territories upfront license fee approval milestones recorded deferred revenue total million million million recognized contract revenue respectively million balance deferred revenue december expected amortized contract revenue period supply hepsera gsk agreement approximately nine years addition gsk required pay us royalties net product sales gsk generates sales hepsera epivirhbvzeffix gsks hepatitis product gsk territories began receiving royalties table contents gilead sciences inc notes consolidated financial statementscontinued december gsks sales hepsera first quarter recorded million million million royalty revenue respectively recognize royalty revenue gsk quarter following quarter related hepsera sales occur result acquisition myogen november assumed rights march license distribution supply agreements myogen gsk terms license agreement gsk received exclusive sublicense rights ambrisentan certain hypertensive conditions territories outside united states received upfront payment subject achievement specific milestones eligible receive additional milestone payments addition receive stepped royalties based net commercial sales ambrisentan gsk territory gsk option negotiate us exclusive sublicense additional therapeutic uses ambrisentan gsk territory term license agreement continue conduct bear expense clinical development activities believe required obtain maintain regulatory approvals ambrisentan united states canada european economic area party may conduct additional development activities territory expense parties may agree jointly develop ambrisentan new indications licensed field party pay share external costs associated joint development acquisition date myogen recorded million deferred revenue legal performance obligations license agreement amortizing deferred revenue contract revenue period performance obligations agreement approximately eight years terms license agreement distribution supply agreement received exclusive rights market promote distribute flolan sterile diluent flolan united states april osi pharmaceuticals inc march entered agreement osi pharmaceuticals inc osi successor eyetech pharmaceuticals inc relating macugen macugen inhibitor vascular endothelial growth factor vegf known play role development certain ophthalmic diseases terms agreement osi received worldwide rights therapeutic uses macugen responsible rd costs entitled receive payments osi osi reaches certain milestones well royalties worldwide net sales macugen subject obligation make payments third parties relating royalties february macugen approved european union june recognized million milestone payment osi relating first commercial sale macugen european union included contract revenue agreement osi expires upon later ten years first commercial sale product developed date last patent expires agreement additionally received warrant purchase shares eyetech series b convertible preferred stock exercisable price per share price stock issued investors see note discussion warrant eventual sale eyetech shares december entered agreement osi fill finish macugen osi initial term ending january recorded contract revenue million million million respectively connection clinical supplies provided osi milestones achieved osi recognized contract revenue million milestone payments osi table contents gilead sciences inc notes consolidated financial statementscontinued december related filings new drug applications europe united states macugen january osi received fda approval sale macugen united states astellas pharma inc entered agreement astellas pharma inc astellas successor fujisawa usa inc related rights market ambisome terms agreement amended astellas responsible promotion ambisome united states astellas sole marketing rights ambisome canada exclusive marketing rights ambisome rest world subject obligation pay royalties astellas connection sales significant markets asia including china india japan republic korea taiwan connection us sales astellas purchases ambisome us manufacturing cost sales canada astellas purchases ambisome manufacturing cost plus specified percentage astellas collects payments sale ambisome united states canada receive royalties equal astellass gross profits sale ambisome united states canada gross profits include deduction cost goods sold giving us current effective royalty rate approximately astellass net sales ambisome united states connection agreement recorded royalty revenue million million million longterm obligations total longterm obligations consist following thousands december capital lease obligations monthly installments interest rates ranging convertible senior notes longterm loan quarterly installments interest rates libor plus tiered contractual rate total longterm obligations less current portion total longterm obligations future minimum payments longterm obligations follows thousands capital lease longterm year ending december obligations loan total less amount representing interest total table contents gilead sciences inc notes consolidated financial statementscontinued december convertible senior notes april issued million principal amount convertible senior notes due notes million principal amount convertible senior notes due notes collectively notes private placement pursuant rule securities act amended notes notes issued par bear interest rates respectively debt issuance costs million connection issuance notes recorded noncurrent assets amortized interest expense straightline basis contractual terms notes aggregate principal amount notes sold reflects full exercise initial purchasers option purchase additional notes cover overallotments notes may convertible based initial conversion rate shares per principal amount notes represents initial conversion price approximately per share notes may convertible based initial conversion rate shares per principal amount notes represents initial conversion price approximately per share notes may converted subject adjustment following circumstances calendar quarter beginning september closing price common stock least trading days last consecutive trading day period previous quarter applicable conversion price per share make specified distributions holders common stock specified corporate transactions occur last month prior maturity applicable notes upon conversion holder would receive amount cash equal lesser principal amount note ii conversion value notes conversion value exceeds may also deliver option cash common stock combination cash common stock conversion value excess notes converted connection change control may required provide makewhole premium form increase conversion rate subject stated maximum amount addition event change control holders may require us purchase portion notes purchase price equal principal amount notes plus accrued unpaid interest thereon december fair values notes notes approximately million million respectively based quoted market values concurrent issuance notes purchased convertible note hedges private transactions cost million cover subject customary antidilution adjustments million shares common stock strike prices correspond initial conversion prices notes market value per share common stock time conversion notes strike price applicable convertible note hedges entitled receive counterparties transactions cash shares common stock combination cash common stock option excess market price common stock strike price convertible note hedges convertible note hedges terminate upon maturity related notes none related notes remain outstanding due conversion otherwise also sold warrants acquire million shares common stock subject customary antidilution adjustments private transactions received net proceeds million market value common stock time exercise applicable warrants exceeds respective strike prices required net settle cash shares common stock option respective counterparties value warrants excess warrant strike prices maximum number shares common stock could issued us choose net share settle warrants million shares underlying share amount warrants strike prices per share warrants expiring per share warrants expiring exercisable respective expiration dates taken together convertible note hedges warrants intended reduce potential dilution upon future conversions notes effectively increasing initial conversion price per share notes per share notes net cost million convertible note hedges warrant transactions recorded stockholders equity table contents gilead sciences inc notes consolidated financial statementscontinued december choice settling convertible note hedges warrants cash shares stock contracts meet applicable criteria equity classification outlined eitf issue accounting derivative financial instruments indexed potentially settled companys stock cost convertible note hedges net proceeds sale warrants classified stockholders equity addition contracts classified stockholders equity indexed common stock accounted derivatives sfas also recorded deferred tax asset million apic effect future tax benefits related convertible note hedges accordance sfas eitf income tax consequences issuing convertible debt beneficial conversion feature contemporaneously closing sale notes portion net proceeds notes issuance proceeds warrant transactions used repurchase million shares common stock million stock repurchase program terms notes agreements require us comply certain covenants december compliance covenants december issued million convertible senior notes due december notes convertible total shares common stock per share convertible senior notes provisionally redeemable whole part option time june specified redemption prices plus accrued interest called convertible senior notes redemption october issued shares common stock note holders upon conversion november redemption price equal principal amount notes redeemed plus accrued unpaid interest redemption date connection redemption made makewhole payment million note holders representing equivalent per principal value notes less interest actually paid accrued unpaid date issuance notes redemption date upon conversion million unamortized balance related debt issuance costs reclassified apic credit facilities december entered agreement syndicate banks fiveyear million senior credit facility million facility consisted uncollateralized million term loan entered gilead biopharmaceutics ireland corporation gbic one whollyowned irish subsidiaries uncollateralized million revolving credit facility entered us parent company gilead sciences inc proceeds term loan used gbic december facilitate cash dividend distribution million parent company part repatriation qualified foreign earnings provisions american jobs creation act ajca terms term loan minimum amount principal payment required repaid end calendar quarter beginning march five percent outstanding balance interest accrued rate libor plus tiered contractual rate basis points payable quarterly arrears gbic prepay term loan together accrued interest prepaid principal time whole part without penalty premium year ended december million term loan principal repaid outstanding interest principal december payable demand us parent company another whollyowned subsidiary gilead vintage park llc guarantors december outstanding principal term loan million table contents gilead sciences inc notes consolidated financial statementscontinued december terms revolving credit facility interest accrued payable rate libor plus tiered contractual rate basis points payable quarterly arrears parent company prepay outstanding borrowings together accrued interest prepaid principal time whole part without penalty premium outstanding interest principal december payable demand capacity revolving credit facility increase maximum million term loan repaid ability irrevocably cancel unutilized portion revolving credit facility whole part proceeds obtained revolving credit facility expected used working capital capital expenditures general corporate purposes including issuance letters credit million gilead vintage park llc guarantor december revolving credit facility increased million result cumulative principal repayments million made term loan december borrowings revolving credit facility january received waivers noncompliance total debt total capitalization financial covenants year ended december contained credit agreements underlying million credit facility acquisition related iprd charges billion recorded fourth quarter purchased iprd caused us comply financial covenants concurrent waiver prospectively amended credit agreements exclude iprd charges recorded commencing october definition total consolidated stockholders equity used calculation total capitalization total debt total capitalization ratio contained credit agreements commitments contingencies lease arrangements entered various longterm noncancelable operating leases equipment facilities facility leases san dimas california durham north carolina westminister colorado seattle washington dublin area ireland london area united kingdom expire various dates durham lease two sevenyear renewal options westminister lease two fiveyear renewal options leases ireland united kingdom years respectively rent subject increase fifth anniversary respective commencement dates also operating leases sales marketing administrative facilities europe canada australia various terms equipment leases include two corporate aircrafts varying terms one provides us renewal option upon expiration lease term lease expense operating leases totaled approximately million million million aggregate noncancelable future minimum rental payments operating leases years ending december follows thousands thereafter table contents gilead sciences inc notes consolidated financial statementscontinued december legal proceedings number states counties municipalities filed complaints alleging large number pharmaceutical company defendants including gilead instances reported inaccurate prices products causing governmental entity named plaintiff overpay pharmaceutical products furnished participants medicaid program separate actions filed new york city numerous new york counties consolidated multidistrict litigation proceeding united states district court district massachusetts august cases voluntarily dismissed respect gilead august october two similar actions state alabama v abbott laboratories inc et al currently pending circuit court montgomery county alabama state mississippi v abbott laboratories inc et al currently pending chancery court first judicial district hinds county mississippi voluntarily dismissed respect gilead knowledge named three additional cases county erie v abbott laboratories inc et al currently pending supreme court state new york county erie county oswego v abbott laboratories inc et al currently pending supreme court state new york county oswego county schenectady v abbott laboratories inc et al currently pending supreme court state new york county schenectady complaints assert claims state law seek damages cases treble damages attorneys fees intend defend cases vigorously cases preliminary stage possible predict outcome amounts accrued related outcome cases may united states district court northern district california executed orders dismissing entirety prejudice fourth consolidated amended complaint associated purported class action lawsuit gilead chief executive officer chief financial officer former executive vice president operations executive vice president research development senior vice president manufacturing senior vice president research alleging defendants violated federal securities laws specifically sections b securities exchange act amended rule b promulgated securities exchange commission making certain alleged false misleading statements plaintiffs appealed dismissal september received service amended complaint adding us defendant colahan v ward et al case filed superior court district columbia plaintiff action misdiagnosed hiv participated emtricitabine clinical trial alleges negligent conduct clinical trial seeks damages defendants jointly severally deny liability intend defend action vigorously case preliminary stage possible predict outcome amounts accrued related outcome case november received subpoena united states attorneys office san francisco requesting documents regarding marketing medical education programs truvada viread emtriva intend comply us attorneys subpoena cooperate related government investigation also party various legal actions arose ordinary course business believe legal actions material adverse impact business consolidated results operations financial position table contents gilead sciences inc notes consolidated financial statementscontinued december commitments contingencies normal course business entered various firm purchase commitments api inventoryrelated items december consist following next five years million million million million million stockholders equity stock repurchase program march board directors board authorized program repurchase common stock amount billion two year period stock repurchases program may made open market private block transactions pursuant rule b plans privately negotiated purchases means including accelerated stock repurchase transactions similar arrangements timing actual number shares repurchased depend variety factors including price corporate regulatory requirements market conditions april repurchased retired million shares common stock per share aggregate million remaining authorized amount stock repurchases may made stock repurchase program terminates march million use par value method accounting stock repurchases par value method common stock first charged par value shares involved excess cost shares acquired par value allocated apic based estimated average sales price per issued share excess amounts charged accumulated deficit result stock repurchase april reduced common stock apic million retained earnings million preferred stock shares authorized preferred stock issuable series board authorized determine designation powers preferences rights series may increased number shares preferred stock potential issuance november rights agreement chasemellon shareholder services llc amended rights plan preferred stock outstanding december december rights agreement rights plan provides distribution preferred stock purchase right dividend share common stock purchase rights currently exercisable certain conditions involving acquisition proposed acquisition person group common stock purchase rights permit holders holder purchase common stock discount market price time upon payment specified exercise price per purchase right addition event certain business combinations purchase rights permit purchase common stock acquirer discount market price time certain conditions purchase rights may redeemed board whole part price per purchase right purchase rights voting privileges attached automatically trade common stock october october may board approved amendments rights plan first amendment provided among things increase exercise price right plan extension term plan november october second table contents gilead sciences inc notes consolidated financial statementscontinued december amendment provides among things increase exercise price right plan extension term rights plan october third amendment clarifying amendment entered connection increase number shares preferred stock potential issuance rights plan may stock option plans may stockholders approved adopted equity incentive plan plan stock options nexstar pharmaceuticals inc nexstar triangle corus myogen stock option plans assumed result acquisitions nexstar triangle corus myogen converted options purchase common stock effective closing acquisitions plan broadbased incentive plan allows awards granted employees directors consultants plan provides option grants designated either nonqualified incentive stock options prior january granted nonqualified incentive stock options stock options granted january nonqualified stock options plan employee stock options generally vest five years exercisable period exceed contractual term ten years date stock options issued granted prices less fair value common stock grant date stock option exercises settled newly issued common stock plans previously authorized available pool shares may stockholders approved increase additional number shares common stock available issuance plan assumed coruss stock plan corus plan conjunction acquisition corus options pursuant corus plan issued outstanding august converted options purchase approximately shares common stock remain subject original terms conditions assumed myogens equity incentive plan stock plan collectively myogen plans conjunction acquisition myogen options issued outstanding myogen plans november converted options purchase approximately million shares common stock remain subject original terms conditions shares available future grant corus myogen plans december million shares remaining available future grant plan following table summarizes activity gilead nexstar triangle corus myogen stock option plans option grants presented table exercise prices less fair value underlying common stock grant date shares thousands year ended december weighted weighted weighted average average average exercise exercise exercise shares price shares price shares price outstanding beginning year granted assumed forfeited exercised outstanding end year exercisable end year weighted average grant date fair value table contents gilead sciences inc notes consolidated financial statementscontinued december following summary stock options outstanding stock options exercisable december options aggregate intrinsic value thousands options outstanding options exercisable weighted weighted average average remaining weighted remaining weighted contractual average aggregate contractual average aggregate options life exercise intrinsic options life exercise intrinsic range exercise prices outstanding years price value exercisable years price value total total intrinsic value options exercised year ended december million million million respectively employee stock purchase plan employee stock purchase plan espp employees purchase shares common stock based percentage compensation subject certain limits purchase price per share equal lower fair value common stock offering date purchase date twoyear lookback feature espp causes offering period reset fair value common stock purchase date less original offering date espp purchases employees settled newly issued common stock espps previously authorized available pool shares total million shares common stock reserved issuance espp december million shares remaining available issuance espp restricted stock following summary activity relating nonvested restricted stock awards year ended december weighted average grant date fair shares value nonvested january granted forfeited vested nonvested december total fair value shares vested years ended december million million respectively table contents gilead sciences inc notes consolidated financial statementscontinued december stockbased compensation january adopted provisions sfas r requires fair value sharebased payments employees directors including grants stock options recognized consolidated statements operations applied modified prospective method adoption sfas r stockbased compensation recognized expense requisite service periods consolidated statements operations using graded vesting expense attribution approach nonvested stock options granted prior adoption sfas r using straightline expense attribution approach stock options granted adoption sfas r stockbased compensation expense related stock options recognized adoption sfas r based awards ultimately expected vest gross expense reduced estimated forfeitures sfas r requires forfeitures estimated time grant revised necessary subsequent periods actual forfeitures differ estimates estimated forfeitures based historical experience prior adoption sfas r pro forma information required sfas included forfeitures occurred result adoption sfas r recognize benefit stockbased compensation apic incremental tax benefit realized tax attributes currently available us utilized addition elected account indirect benefits stockbased compensation research tax credit extraterritorial income deduction consolidated statement operations rather apic table summarizes impact adopting sfas r effective january thousands except per share amounts year ended december cost goods sold research development expenses selling general administrative expenses stockbased compensation expense included total costs expenses tax benefit related stockbased compensation expense stockbased compensation expense included net loss stockbased compensation expense included net loss per share basic diluted year ended december capitalized million stockbased compensation costs inventory total fair value stock options vested year ended december million december stockbased compensation expense million related nonvested stock option awards yet recognized expected recognized estimated weighted average period years valuation assumptions fair values awards granted stock option plans espp estimated grant purchase dates using blackscholes option valuation model blackscholes option valuation model developed use estimating fair value traded options vesting restrictions fully transferable table contents gilead sciences inc notes consolidated financial statementscontinued december addition option valuation models require input highly subjective assumptions including expected stock price volatility expected award life connection adoption sfas r refined methodologies used derive valuation model assumptions calculate estimated fair value awards used following assumptions year ended december expected volatility stock options espp expected life years stock options espp riskfree interest rate stock options espp expected dividend yield fair value stock options granted prior adoption sfas r calculated using multiple option approach fair value stock options granted beginning january calculated using single option approach prior adoption sfas r used historical stock price volatility connection blackscholes option valuation model connection adoption sfas r determined blend historical volatility along implied volatility traded options common stock better reflection expected volatility expected life stockbased awards represents weightedaverage period awards expected remain outstanding estimate weightedaverage expected life based historical cancellation historical exercise data related stock options well contractual term vesting terms awards riskfree interest rate based upon observed interest rates appropriate term stockbased awards dividend yield based history expectation dividend payouts comprehensive income loss comprehensive income loss comprises net income loss certain changes stockholders equity excluded net income loss changes fair value outstanding effective cash flow hedges changes unrealized gains losses availableforsale securities changes cumulative foreign currency translation account comprehensive income loss years ended december included consolidated statement stockholders equity components comprehensive income loss shown net related taxes underlying assets liabilities held jurisdictions expected generate future tax benefit liability table contents gilead sciences inc notes consolidated financial statementscontinued december following reclassifications recorded connection net realized gains losses sales securities cash flow hedges previously included comprehensive income loss thousands year ended december net unrealized gain loss related availableforsale securities net tax provision benefit respectively net unrealized gain loss related cash flow hedges net tax provision benefit respectively reclassification adjustments net tax benefit respectively comprehensive income loss balance accumulated comprehensive income net taxes reported consolidated balance sheets consists following components thousands year ended december net unrealized gain loss availableforsale securities net unrealized gain loss cash flow hedges net foreign currency translation gain accumulated comprehensive income disclosures segments enterprise related information operate one business segment primarily focuses development commercialization human therapeutics life threatening diseases products included one segment major products truvada viread atripla emtriva hepsera ambisome together accounted substantially total product sales three years ended december similar economic characteristics including nature products production processes type customers distribution methods regulatory environment product sales consist following thousands year ended december hiv products truvada viread atripla emtriva total hiv product sales hepsera ambisome total product sales table contents gilead sciences inc notes consolidated financial statementscontinued december following table summarizes total revenues external customers collaboration partners geographic region thousands product sales productrelated contract revenue attributed countries based shipto location royalty nonproduct related contract revenue attributed countries based location collaboration partner certain revenue amounts reclassified geographic regions conform current period presentation year ended december united states outside united states switzerland france spain united kingdom italy germany european countries countries total revenues outside united states total revenues december net book value property plant equipment million approximately assets located united states december net book value property plant equipment united states canada million million respectively representing total net book value property plant equipment following table summarizes revenues customers individually accounted total revenues total revenues year ended december cardinal health inc mckesson corp f hoffmannla roche ltd amerisourcebergen corp amount less table contents gilead sciences inc notes consolidated financial statementscontinued december income taxes provision income taxes consisted following thousands year ended december federal current deferred state current deferred foreign current deferred provision income taxes foreign pretax income million million million respectively cumulative unremitted foreign earnings considered permanently invested outside united states us taxes provided approximately million million december respectively residual us tax liability amounts remitted would approximately million million december respectively difference provision income taxes amount computed applying federal statutory income tax rate income loss provision income taxes follows thousands year ended december income loss provision income taxes tax federal statutory rate state taxes net federal benefit foreign earnings different rates inprocess rd charge research credits net unbenefitted stock compensation benefit qualified foreign earnings repatriation benefitted losses change valuation allowance provision income taxes table contents gilead sciences inc notes consolidated financial statementscontinued december deferred income taxes reflect net tax effects temporary differences carrying amounts assets liabilities financial reporting purposes amounts used income tax purposes significant components deferred tax assets liabilities follows thousands year ended december deferred tax assets net operating loss carryforwards convertible note hedges capitalized intangibles research credit carryforwards reserves accruals currently deductible stockbased compensation depreciation related capitalized rd expense net total deferred tax assets valuation allowance valuation allowance total deferred tax assets deferred tax liabilities unremitted foreign earnings total deferred tax liabilities net deferred tax assets valuation allowance million million december december respectively valuation allowance increased decreased million million million years ended december respectively concluded based standard set forth sfas likely realize benefit deferred tax assets related certain state net operating loss carryforwards released million valuation allowance credited goodwill december us federal net operating loss carryforwards approximately million federal net operating loss carryforwards expire various dates utilized also federal tax credit carryforwards approximately million expire utilized addition state net operating loss tax credit carryforwards approximately million million respectively valuation allowance million provided state net operating loss tax credit carryforwards expire various dates respectively utilized utilization net operating losses tax credits may subject annual limitation due ownership change limitations provided internal revenue code amended similar state provisions annual limitation may result expiration net operating losses credits utilization table contents gilead sciences inc notes consolidated financial statementscontinued december deferred tax assets relating tax benefits employee stock option grants reduced reflect exercises exercises resulted tax deductions excess previously recorded benefits based option value time grant additional tax benefits credited apic pursuant sfas r october ajca signed law ajca allowed deduction certain qualified foreign earnings repatriated defined ajca elected apply provision qualifying earnings repatriation fiscal earnings repatriation resulted onetime tax benefit approximately million included reversal deferred tax liability previously accrued unremitted foreign earnings million december internal revenue service irs commenced examination income tax returns tax years believe positions comply applicable laws record liabilities based upon sfas accounting contingencies events occur indicate payment amounts unnecessary reversal liabilities result tax benefits recognized period determine liabilities longer necessary estimate tax liabilities proves less ultimate assessment charge expense result believe provided adequate accruals anticipated tax audit adjustments based estimate whether extent additional taxes interest may due deferred compensation plans maintain one retirement savings plan eligible employees may defer compensation income tax purposes section k internal revenue code gilead plan gilead plan employees may contribute eligible annual compensation subject irs plan limits make matching contributions gilead plan contribute employees first contributions annual maximum match increasing total matching contribution expense gilead plan million million maintain deferred compensation plan directors officers may defer compensation income tax purposes deferred compensation plan nonqualified deferred compensation plan subject qualification requirements section internal revenue code compensation deferred december subject requirements section internal revenue code plan officers may contribute annual salaries annual bonus directors may contribute annual retainer fee amounts deferred participants deposited rabbi trust recorded noncurrent assets consolidated balance sheets beginning directors may also elect receive portion annual cash retainer phantom shares gives participant right receive amount equal value specified number shares specified period time payable shares gilead common stock partial shares paid cash established plan administrator december phantom shares outstanding participants elect one several distribution dates available plan receive deferred compensation payment table contents gilead sciences inc notes consolidated financial statementscontinued december quarterly results operations unaudited following amounts thousands except per share amounts st quarter nd quarter rd quarter th quarter total revenues gross profit product sales total costs expenses net income loss net income loss per sharebasic net income loss per sharediluted total revenues gross profit product sales total costs expenses net income net income per sharebasic net income per sharediluted fourth quarter recognized billion charge purchased iprd associated acquisitions third quarter recognized acquisitionrelated charge million purchased iprd fourth quarter recognized million royalty revenue relating resolution dispute roche fourth quarter recorded onetime tax benefit million related repatriation qualified foreign earnings ajca reclassified million million million million foreign exchange transaction gains losses well fair value changes derivative instruments sga expense interest income net first second third fourth quarters respectively table contents gilead sciences inc schedule ii valuation qualifying accounts balance additions balance beginning charged end period expense deductions period year ended december accounts receivable allowances valuation allowance deferred tax assets year ended december accounts receivable allowances valuation allowance deferred tax assets year ended december accounts receivable allowances valuation allowance deferred tax assets allowances doubtful accounts sales returns cash discounts chargebacks valuation allowance deferred tax assets includes million related acquisitions table contents